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ABSTRACT 
The prescription and use of antipsychotic drugs (APDs) to treat various mental illnesses 
and behavioural disorders in children and adolescents has exponentially increased in 
recent years on a global scale. This significant increase in rates of use across both male 
and female sexes is despite a limited knowledge of what the long-term effects of early 
APD treatment are. With critical neurodevelopmental phases well-known to extend 
through this juvenile time period, there is the potential that exposure to the potent 
actions of APDs on numerous multifunctional neurotransmitter (NT) systems may alter 
brain topography on a long-term and/or permanent basis. Furthermore, alterations to NT 
systems including dopamine (DA) and serotonin (5-HT) have previously been heavily 
implicated in both the pathogenesis of mental illness, and known to play significant 
roles in behavioural attributes such as activity levels and anxiety. With the second 
generation APDs aripiprazole, olanzapine and risperidone three of the most commonly 
prescribed to the juvenile population, and the therapeutic effects of APDs 
predominantly based on a partial agonist and/or antagonist mechanism of action on DA 
and 5-HT receptors and hence modulation of NT signal, this thesis investigated the 
long-term effects of juvenile APD treatment during this critical neurodevelopmental 
time period on adult behavioural attributes, and subsequently uncovered potential long-
term alterations to the DA and 5-HT NT system in the adult brain across both male and 
female cohorts. 
 
The first study, an investigation into potential long-term changes to behavioural 
attributes, demonstrated that juvenile APD treatment resulted in changes to locomotor 
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activity, anxiety and depressive-like behaviours when compared to the control. 
Differing effects upon comparison of sexes were also uncovered. In the male cohort, 
juvenile treatment with olanzapine and risperidone resulted in long-term hyper-
locomotor effects, and a decrease in depressive-like behaviour in those treated with 
olanzapine. Furthermore, an anxiolytic-like effect was observed across all 3 APD 
treatment groups in comparison to controls. Lesser effects were observed in the female 
cohort, with a long-term increase to depressive-like behaviour and hypo-locomotor 
activity exhibited following juvenile treatment with risperidone and olanzapine. Such 
observations clearly indicated the potential for juvenile APD treatment to cause long-
term changes to behavioural attributes into adulthood, long after drug treatment had 
concluded. 
 
With alterations to the DA and 5-HT NT systems well known to play a significant role 
in both APD treatment efficacy, along with the aforementioned behavioural attributes 
and the pathogenesis of various mental illnesses, I further investigated the effects of 
juvenile APD treatment on long-term alterations to both the DA and 5-HT NT systems 
across both male and female cohorts. 
 
Investigations into the effects of juvenile APD treatment on the DA NT system 
uncovered long-term alterations to DA synthesis (TH & p-TH), receptor (D1 and D2 
receptors) and transporter (DAT) levels in mesocortical, mesolimbic, nigrostriatal and 
hippocampal brain regions. In the male cohort, early treatment with risperidone 
increased p-TH levels in both the PFC and hippocampus, and DAT levels in the VTA, 
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whilst decreases to D1 receptor expression in the NAc and DAT levels in the CPu were 
found. Decreases to TH levels in the PFC were also uncovered following early 
aripiprazole treatment. Alterations across all three drug treatment groups were revealed 
in the female cohort, with early aripiprazole treatment decreasing TH and D1 receptor 
levels in the VTA and p-TH levels in the PFC, olanzapine treatment decreasing p-TH 
levels in the PFC and increasing the D2 receptor expression in the PFC and NAc and 
early risperidone treatment increasing D1 receptor levels in the hippocampus. These 
results clearly indicated the capability of APD treatment during critical phases of 
neurodevelopment to elicit long-lasting and potentially permanent changes to the way 
the DA NT system functions. Furthermore, differing effects across sexes and 
investigated drug treatment groups were also uncovered.  
 
Along with investigations into the long-term effects on the DA NT system, I also 
investigated alterations to 5-HT1A, 5-HT2A and 5-HT2C receptors in the cortical, 
hippocampal and striatal brain regions, previously found to play significant roles in both 
the therapeutic efficacy of APDs and furthermore the pathogenesis of various mental 
illnesses. Juvenile treatment with APDs in the male cohort was found to elicit long-term 
changes across all three receptor subtypes. Early risperidone treatment resulted in 
decreases to 5-HT1A receptors in the PFC and NAc and 5-HT2A receptors in the PFC and 
hippocampus, whilst increases to 5-HT2C receptors were observed in the hippocampus. 
Olanzapine treatment was found to decrease 5-HT2A and 5-HT2C receptor expression in 
the hippocampus and PFC respectively, whilst juvenile aripiprazole treatment was 
found to decrease 5-HT2A and 5-HT2C levels in the PFC, and increase 5-HT2C 
expression in the hippocampus. Lesser alterations to the 5-HT receptors were found in 
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the female cohort, with early risperidone and olanzapine treatment resulting in a 
decreased 5-HT2A receptor density levels in the hippocampus, and aripiprazole 
decreasing 5-HT1A receptor levels in the NAc. It is therefore evident that juvenile APD 
treatment also has the potential to result in long-lasting changes to the density of 5-HT 
receptors, well-known to play significant roles in both the mechanism of action and 
therapeutic efficacy of APD treatment.  
 
In summary, this thesis provides foundational evidence that juvenile treatment with the 
commonly prescribed APDs aripiprazole, olanzapine and risperidone has the potential 
to elicit long-term changes to various behaviours, and furthermore result in long-lasting, 
permanent alterations to the functioning of both the DA and 5-HT NT systems in 
adulthood. 
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CHAPTER 1 - GENERAL INTRODUCTION 
The prescription and use of antipsychotic drugs (APDs) in children and adolescents has 
exponentially increased on a worldwide scale in recent times, despite serious limitations 
in the safety and efficacy of APD use in these population groups (Rani et al. 2008; 
Varley and McClellan 2009; Olfson et al. 2010; Alexander et al. 2011; Olfson et al. 
2012; Seida et al. 2012; Hoekstra 2014; Sharma et al. 2016). In particular, second  
generation APDs (e.g. aripiprazole, olanzapine and risperidone) are commonly 
prescribed (mostly off-label) for treating various childhood disorders; from  mental 
illnesses including anxiety and child-onset schizophrenia (Olfson et al. 2010; Memarzia 
et al. 2014; Schneider et al. 2014), to various behavioural disorders (Haw and Stubbs 
2007; Vitiello et al. 2009; Sharma and Shaw 2012). Whilst APDs are known to elicit 
their therapeutic efficacy mostly through antagonist or partial agonist actions on the 
dopamine (DA) and serotonin (5-HT) neurotransmitter (NT) systems, the dopaminergic 
and serotonergic systems are also heavily involved in and undergo multiple critical 
neurodevelopmental processes during this juvenile time period (Levitt et al. 1997; Frost 
and Cadet 2000; Andersen 2003; Andersen and Navalta 2004; Yildirim et al. 2008; 
Klomp et al. 2012; Milstein et al. 2013; Cousins and Goodyer 2015). There is therefore 
the potential for APD use in such a critical neurodevelopmental time period to carry a 
substantial risk of long-term alterations to the functioning (from NT synthesis to 
transport and binding to receptors) of the DA and 5-HT NT systems in the adult brain, 
with significant implications to the pathogenesis of mental illness (Andersen and 
Navalta 2004; Marco et al. 2011; Bottelier et al. 2014; De Santis et al. 2016).  
Therefore, this thesis investigated the long-term effects of childhood/adolescent APD 
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treatment with aripiprazole, olanzapine and risperidone on adult behavioural attributes, 
and subsequent changes to the DA and 5-HT NT systems in relevant brain regions.  
 
The investigation in Chapter 3 showed evidence that early treatment (Postnatal Day 
(PD) 22-50) with aripiprazole (1 mg/kg, three times daily (t.i.d.)), olanzapine (1 mg/kg, 
t.i.d.) and risperidone (0.3 mg/kg, t.i.d.) resulted in long-term changes to behavioural 
attributes in the adult rat across both male and female sexes. Following an early drug 
treatment period during a human equivalent time of childhood/adolescence in humans 
(PD 22-50) (Andersen 2003) APD treatment was ceased, and a brain maturation period 
of no drug treatment (PD 51-71) ensued. Following this time period mature, adult rats 
were put through a series of behavioural tests (from PD 72-94) including open-
field/holeboard, elevated plus maze (EPM), social interaction and forced swim (FS) 
tests to investigate potential changes to behavioural attributes including locomotor 
activity, anxiety-like, depressive-like and social behaviours. The study found that in the 
male cohort, early treatment with risperidone, and olanzapine resulted in long-term 
hyper-locomotor effects (demonstrated in the open-field/holeboard and FS tests), whilst 
a decrease in depressive-like behaviour was also revealed in the olanzapine treatment 
group following analysis of FS test results. Lesser effects were uncovered to the female 
cohort, with alterations to FS test results demonstrating an increase in depressive-like 
behaviour following juvenile drug treatment with risperidone and olanzapine. These 
results demonstrated that juvenile APD treatment causes long-term changes to adult 
behavioural attributes, including locomotor activity, anxiety and depressive-like 
behaviours, with clear differences in effects across sexes.  
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As mentioned previously, with changes to the aforementioned behavioural attributes 
previously linked to alterations to both the DA and 5-HT NT systems (Karl et al. 2006; 
Seo et al. 2008; de Oliveira et al. 2009; Beaulieu and Gainetdinov 2011; Biojone et al. 
2011), and APDs known to elicit their therapeutic effects through actions predominantly 
on DA and 5-HT receptors (Meltzer 2002; Meltzer et al. 2003; Grace et al. 2007; 
Kegeles et al. 2010; Purves-Tyson et al. 2012; Milstein et al. 2013), this supported the 
case for further research into potential long-term alterations to the DA and 5-HT NT 
systems which may have resulted in the observed effects. The focus for the 
investigations of Chapters 4 and 5 therefore delved into potential long-term alterations 
to the adult DA (Chapter 4) and 5-HT (Chapter 5) NT systems following the juvenile 
APD treatment period, utilising the brain tissue from the animal cohort detailed in 
Chapter 3. Following the period of behavioural testing described above (PD 72-94), 
animals were then allowed to rest with access to food and water until PD 106, when 
they were sacrificed and brain tissue was collected for use in western blot and receptor 
autoradiography experiments. 
 
Chapter 4 subsequently details the results of the long-term effects of early APD 
treatment on the DA NT system. Specifically, we investigated the effects of 
aripiprazole, olanzapine and risperidone on DA synthesis (tyrosine hydroxylase (TH) 
and phosphorylated-tyrosine hydroxylase (p-TH)), dopamine active transporter (DAT) 
and D1 and D2 receptor levels in cortical and striatal brain regions, along with the 
hippocampus, substantia nigra and ventral tegmental area, regions known to play key 
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roles in the synthesis and regulation of the DA signal. Clear long-term alterations to the 
DA NT system were uncovered, and furthermore the observed results demonstrated 
clear differences in the effects of early APD treatment upon comparison of sexes. 
Alterations in the female cohort included decreases to synthesis markers (TH and p-TH) 
and increases in D2 receptor density levels in mesocortical brain regions following early 
aripiprazole and olanzapine treatment, whilst no alterations were uncovered in 
risperidone drug treatment groups. In the male cohort however, alterations were almost 
exclusively restricted to the risperidone drug treatment group in comparison to control, 
with increases to DA synthesis and re-uptake markers were observed across 
mesocortical, hippocampal and striatal brain regions. Additionally, changes in DA D1 
receptor levels only were observed, with no changes to D2 receptor detected. These 
results clearly demonstrated that whilst early treatment with APDs results in long-term, 
potentially permanent alterations to the functioning of the DA NT system, there are 
clearly also dissimilarities in their effects on the male and female sexes.  
 
Investigations into potential changes to the 5-HT NT system following early APD 
treatment are described in Chapter 5. In particular, we investigated the long-term effects 
of juvenile APD treatment with aripiprazole, olanzapine and risperidone on 5-HT1A, 5-
HT2A and 5-HT2C receptor subtypes, in cortical, striatal and hippocampal brain regions, 
all known to play key roles in the therapeutic mechanisms of APD action. Once again 
significant changes to 5-HT receptor subtypes were uncovered in the adult brain 
following the juvenile APD treatment period, in particular the 5-HT2A and 5-HT2C 
receptor subtypes in cortical and hippocampal brain regions. Furthermore, clear 
variances between sexes were once again uncovered, with the majority of alterations 
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found in the male cohort. Specifically, decreases to 5-HT2A receptors were uncovered in 
cortical and hippocampal brain regions across all 3 drug treatment groups in the male 
cohort, and 5-HT2C density levels in cortical regions following early aripiprazole 
treatment. Increases to hippocampal 5-HT2C receptor density levels were also found 
following early aripiprazole and risperidone treatment. Decreases to 5-HT1A receptors 
were also found in cortical and striatal regions following early risperidone treatment. As 
mentioned previously, lesser effects were found in the female cohort, with decreases to 
5-HT2A receptor density levels in hippocampal brain regions following early olanzapine 
and risperidone drug treatment, whilst early aripiprazole treatment was found to 
decrease 5-HT1A receptor levels in the NAc. These results clearly demonstrated that 
APD treatment during the critical neurodevelopmental time period of 
childhood/adolescence results in permanent alterations to 5-HT receptor density levels. 
The results of this investigation once again clearly indicated that early APD treatment 
with aripiprazole, olanzapine and risperidone has the potential to cause long-term, 
permanent alterations to 5-HT receptors, in particular across cortical and hippocampal 
brain regions in the male cohort. 
 
In conclusion, this thesis has uncovered that APD treatment during the critical 
neurodevelopmental time period of childhood/adolescence results in long-term changes 
to various behavioural attributes, and permanent alterations to various receptor 
subtypes, synthesis and re-uptake markers in the DA and 5-HT NT systems. 
Additionally, sex and drug specific differences in treatment effects were also evident. 
With APDs known to have high affinities for both the DA and 5-HT NT systems to 
elicit their therapeutic effects, and both DA and 5-HT also known to play key roles in 
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the modulation of various behavioural attributes and in the pathophysiology of 
numerous mental illnesses, treatment during such a critical period of neurodevelopment 
has clearly resulted in permanent changes to the functioning of both NT systems in the 
mature, adult brain. Increasing the awareness of the potential long-term, permanent 
effects of the prescription and use of APDs in children and adolescents on adult 
behaviours and the DA and 5-HT NT systems will allow clinicians to weigh up the 
potential risks vs benefits of prescribing APD treatment during such a critical time of 
neurodevelopment. Furthermore, the results of the current thesis has shed light on the 
fact that careful consideration needs to be cast over both the pharmacology of the APD 
being prescribed, and also the sex of the child being treated. 
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CHAPTER 2 – LITERATURE REVIEW 
2.1 Introduction 
Long-term mental illnesses have been found to affect 13-20% of children globally 
(Younger 2017) and is an important public health problem in Australia, seen to impact 
approximately 14% of Australian children and adolescents (Sawyer et al. 2001). Whilst 
the exact processes involved in the pathogenesis of mental illness are still mostly 
unknown, evidence suggests that both the dopamine (DA) and serotonin (5-HT) 
neurotransmitter (NT) systems play crucial roles in the aetiology of various mental 
disorders such as childhood-onset schizophrenia, bipolar disorder and psychosis. 
Alterations to the functioning of both the DA and 5-HT NT systems, including changes 
to various pre- and post-synaptic receptor subtypes, especially the DA D1, D2 and 5-
HT1A and 5-HT2A/2C receptors along specific pathways/areas of the brain have been 
implicated in the pathogenesis of numerous mental illnesses. The aforementioned 
changes and subsequent dysregulation of the neurotransmission of both DA and 5-HT 
has hence associated both the DA and 5-HT system in the mechanisms underlying the 
disease state (Grace 2000; Lewis and Lieberman 2000; Feenstra et al. 2001; DeLeon et 
al. 2004; Conley and Kelly 2005; Grace et al. 2007; Nasrallah 2008; Correll 2010).  
 
Antipsychotic drugs (APDs) have been used as a basis of treatment of various mental 
illnesses for over 50 years (Gray and Roth 2007; Correll 2010), however recent 
investigations into the trends of APD prescription and use have exposed significant 
increases in the prescription and use in the juvenile population globally (Olfson et al. 
2006; Danielyan et al. 2007; Rani et al. 2008; Varley and McClellan 2009; Egger 2010; 
Olfson et al. 2010; Alexander et al. 2011; Olfson et al. 2012; Seida et al. 2012; Hoekstra 
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2014; Karanges et al. 2014). Alarmingly, significant levels of off-label prescription and 
use within the juvenile population was also highlighted (Haw and Stubbs 2007; 
Alexander et al. 2011). Whilst second generation APDs (including aripiprazole, 
olanzapine and risperidone) are known to produce varying levels of therapeutic benefits 
to patients with a higher safety profile than their first generation counterparts (Findling 
et al. 2005; Vitiello et al. 2009; Zuddas et al. 2011), their potent affinity and 
mechanisms of action on DA and 5-HT receptors during  what is a crucial period of 
brain development has highlighted the potential for long-term, potentially permanent 
alterations to brain functioning, in particular changes to the DA and 5-HT NT systems.  
Therefore, investigating the potential long-term effects of juvenile treatment with the 
commonly prescribed APDs aripiprazole, olanzapine and risperidone on adult 
behavioural attributes, and furthermore potential permanent changes to the DA and 5-
HT NT systems, will provide an important insight for physicians, allowing them to 
weight up the risk vs benefit ratio of prescribing APDs to the juvenile population.  
 
 
2.2 Literature Review 
  Antipsychotic Drugs  2.2.1
2.2.1.1 Overview of APDs 
APDs have been used since the 1950s to provide relief to sufferers of various mental 
illnesses. Decades of research into the pathology of mental illness have led to the 
continual development of new APDs with a greater therapeutic efficacy and lesser 
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detrimental side effects, used as a treatment for a wide range of mental disorders 
(Correll 2008; Almandil et al. 2013; Deng 2013).  Two ‘generations’ of APDs have 
subsequently been developed, categorised according to their clinical action and/or 
mechanism of action. Pharmacological analysis of all APDs has found that whilst the 
majority of APDs display a high affinity of the DA NT system (in particular the DA D2 
receptor) (Feenstra et al. 2001; DeLeon et al. 2004; Conley and Kelly 2005; Nasrallah 
2008; Correll 2010), corresponding affinities/actions on other NT systems including the 
5-HT NT system and receptors in order to regulate neurotransmission is also correlated 
with and critical to recent advances in treatment and an increased therapeutic efficacy 
(Kapur and Remington 1996; Moore et al. 1999; Meltzer and Huang 2008). 
 
In particular, the actions of APDs on DA D2 receptors and 5-HT2A receptors in regions 
encompassing the mesolimbic, mesocortical and nigrostriatal pathways have been 
highlighted as essential in the alleviation of psychotic symptomology, and increased 
cognitive abilities (Grace et al. 2007; Kegeles et al. 2010; Purves-Tyson et al. 2012). 
Whilst their affinities for, and mechanism of action on certain NT groups (including 
both  the DA and 5-HT NT systems) are key to their ability to reduce psychosis (Kane 
and Freeman 1994), severe detrimental side effects are seen to correlate with first and 
second generation APD use. Moreover, therapeutic benefits have also been found with 
prescription and use of the aripiprazole, an example of an APD with a partial agonist 
mechanism of action across multiple DA and 5-HT receptors, with far fewer side effects 
(DeLeon et al. 2004; Han et al. 2009). 
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2.2.1.2 First Generation APDs 
First generation APDs (also known as ‘typical’ or ‘conventional’ antipsychotics) were 
the first effective form of treatment of some symptomology of numerous mental 
illnesses, including schizophrenia. First generation APDs have a high affinity for 
dopaminergic receptors (e.g. Haloperidol; Ki value 1.4nM for D2 receptors, 21nM for 
D3 receptors and 11nM for D4 receptors) (Table 1) (DeLeon et al. 2004; Conley and 
Kelly 2005; Kusumi et al. 2015), with its potent non-selective antagonism of these 
receptor subtypes causing alleviation of some symptomology of mental illness (Seeman 
et al. 1976; Creese et al. 1996; Ginovart and Kapur 2012).  
 
Although very effective in the treatment of various facets of the symptomology of 
mental illness, particularly the positive symptoms of schizophrenia, 1
st
 generation APDs 
have also been found to have very limited benefits in treating other symptomology, 
including negative symptoms and cognitive deficits (Agid et al. 2008). Furthermore, 
while providing their therapeutic benefits, the potent, non-selective antagonism of DA 
receptors (DA D2 receptor inclusive) by first generation APDs has been strongly linked 
with inducing the observed Extrapyramidal Symptoms (EPS; e.g. tardive dyskinesia and 
Parkinsonism) at a very high rate (Tarsy and Baldessarini 2006). The therapeutic 
efficacy and side effects (e.g. EPS) induced by first generation APDs have been linked 
to the potent antagonism of D2 receptors in the mesolimbic and nigrostriatal 
dopaminergic pathways (Seeman et al. 1976; Creese et al. 1996; Kapur and Mamo 
2003; Tarsy and Baldessarini 2006; Ginovart and Kapur 2012), of which are some of 
the neuronal areas of interest in the present study. 
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2.2.1.3 Second Generation APDs 
In the 1960s, the first of the second generation of APDs (also known as atypical 
antipsychotics) - clozapine (Clozaril) was developed, and was first used clinically in the 
1970s. Further second generation APD development soon followed, including 
olanzapine (Zyprexia), ziprasidone (Geodon) and risperidone (Risperdal), all of which 
were used clinically in the treatment of various mental illnesses including schizophrenia 
(Kane and Freeman 1994). In comparison to their first generation counterparts, the 
newly developed second generation APDs have an increased therapeutic efficacy in the 
treatment of the multi-faceted symptomology of various mental illnesses (Cleghorn et 
al. 1990; Danion et al. 1999; Ho et al. 1999; Conley and Kelly 2005). 
 
Whilst the exact pharmacological mechanisms of action behind second generation APD 
efficacy are complicated, investigations have uncovered a lower affinity and less potent 
antagonistic actions on dopaminergic receptor groups than their first generation 
counterparts. As demonstrated in Table 1, second generation APDs have a more 
extensive affinity for multiple neuroreceptor groups (Scatton and Sanger 2000; Feenstra 
et al. 2001; DeLeon et al. 2004; Nasrallah 2008; Correll 2010; Kusumi et al. 2015), 
encompassing 5-HT (e.g. risperidone Ki value: 0.16 for 5-HT2A receptors), muscarinic 
(e.g. clozapine Ki value: 1.4 for M1 receptors), histaminergic (e.g. olanzapine Ki value: 
3.5 for H1 receptors) and α adrenergic receptors (e.g. clozapine Ki value: 6.8 for α1 
receptors) (Mathews and Muzina 2007; Correll 2010). Whilst the lower antagonistic 
potency of second generation APDs at the DA D2 receptors has been correlated to fewer 
EPS than were found with first generation APD use, second generation drug treatment 
has been found to potentially induce weight gain and other metabolic disorders (e.g. 
Michael De Santis  12 
 
cardiovascular disease and type II diabetes) (Lieberman et al. 2005; Zipursky et al. 
2005; Ujike et al. 2008; Weston-Green et al. 2008; Patel et al. 2009), with antagonism 
of histamine H1 receptors in particular previously correlated with such side effects 
(Deng et al. 2010; He et al. 2013). 
 
Although second generation APDs are known to elicit widespread effects across 
multiple neuroreceptor groups, a common pharmacological profile on DA and 5-HT 
receptors (located on dopaminergic neurons in mesolimbic and mesocortical brain 
regions) is known to play a key role in achieving their increased therapeutic effects 
(Duncan et al. 1999; Farah 2005; Meltzer and Huang 2008; Meltzer and Massey 2011). 
Of particular importance is APD occupation of DA receptors (in particular the DA D2 
receptor), with an optimal occupancy rate of between 65-80% found crucial to 
achieving the greatest therapeutic benefits and least EPS side effects (Seeman 2011; 
Ginovart and Kapur 2012). Furthermore, the increased antagonistic affinity for 5-HT2A 
receptors in comparison to DA D2, and higher antagonistic actions for 5-HT2A and 5-
HT2C receptors is thought to be the basis of difference between the vast majority of first 
and second generation APDs (Meltzer and Massey 2011). Previous studies have found 
that the antagonism of second generation APDs (e.g. olanzapine) on 5-HT2A and 5-HT2C 
receptors facilitates the release of DA in cortical, striatal and hippocampal brain regions, 
which is correlated to the alleviation of mental illness symptomology (Di Matteo et al. 
2001; Horacek et al. 2006; Kuroki et al. 2008). 
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Table 1 – Receptor binding affinities for 1
st
 and 2
nd
 Generation APDs. 
Receptor HAL 
(Ki) 
OLAN 
(Ki) 
RISP 
(Ki) 
ARIP 
(Ki) 
D1 270 250 620 1960 
D2 1.4 17 3.3 0.74 
D3 21 54 13 1.0 
D4 11 28 16 510 
5-HT1A 3081 2720 250 5.6 
5-HT2A 25 1.9 0.16 8.7 
5-HT2C >5000 7.1 63 76 
α1 19 60 2.3 26 
H1 727 3.5 2.6 25 
M1 >1500 1.9 >10 000 >10 000 
Abbreviations: HAL- haloperidol; RISP- risperidone; OLAN- olanzapine; ARIP- aripiprazole; 
D1 = dopamine1; D2 = dopamine2; D3 = dopamine3; D4 = dopamine4; 5-HT1A = serotonin1A; 5-
HT2A = serotonin2A; 5-HT2C = serotonin2C; H1 = histamine1; M1 = muscarinic1. Note: All values 
documented as Ki values (nM). 
(Feenstra et al. 2001; DeLeon et al. 2004; Nasrallah 2008; Correll 2010; Kusumi et al. 2015) 
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2.2.1.4 Further Development of Second Generation APDs 
Aripiprazole is one of the newest APDs developed, and has been observed to have a 
more favourable safety and tolerability profile than its predecessors. Whilst it can be 
categorized as a second generation APD, it has been found to display a unique 
mechanism of action, different from that of other second generation APDs (Mailman 
and Murthy 2010). This enhanced therapeutic efficacy with low incidence of 
detrimental side-effects has been attributed mostly to its partial agonist mechanism of 
action at DA D2 receptor (Burris et al. 2002; Shapiro et al. 2003; DeLeon et al. 2004; 
Wood and Reavill 2007; Etievant et al. 2009; Natesan et al. 2011). It has been found to 
exhibit a very high affinity (Ki value: 0.45 nM) (Table 1) (DeLeon et al. 2004; Correll 
2010; de Bartolomeis et al. 2015) and high occupancy rate for D2 receptors (more than 
90%) at the regular clinical dosage rate of 15-30mg (Yokoi et al. 2002; DeLeon et al. 
2004; Hamamura and Harada 2007). Based on these differences in pharmacology, 
aripiprazole has also been classified as a third generation APD in some literature 
(Newman-Tancredi et al. 2007; Mailman and Murthy 2010). This thesis however will 
follow the literature classification of aripiprazole that defines it as being a second 
generation APD. 
 
As evident in Table 1, aripiprazole also has a high affinity for 5-HT1A and 5-HT2A 
receptors. Additionally, studies into the pharmacology of aripiprazole have discovered a 
partial agonist mechanism of action at 5-HT1A and a partial antagonist mechanism of 
action for 5-HT2A receptors (Shapiro et al. 2003; DeLeon et al. 2004; Newman-Tancredi 
et al. 2005; Mamo et al. 2007; Correll 2010; Mailman and Murthy 2010; de Bartolomeis 
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et al. 2015). Furthermore, there is evidence that at relevant therapeutic doses, 
aripiprazole has a low occupancy and activity at 5-HT1A and 5-HT2A receptors, rather 
acting predominantly on DA D2 receptors (Mamo et al. 2007; Wood and Reavill 2007). 
Our laboratory has also found evidence that long-term aripiprazole treatment did not 
affect 5-HT1A receptors (Han et al. 2009). Despite these high affinity and occupancy 
rates for DA D2 receptors (Yokoi et al. 2002; DeLeon et al. 2004; Hamamura and 
Harada 2007; Correll 2010), the therapeutic benefits of aripiprazole have been 
correlated with very low rates of the EPS discussed earlier compared with first 
generation APDs (e.g. Haloperidol). Furthermore, a very low rate of metabolic side-
effects (seen with other second generation APDs such as clozapine and olanzapine) has 
been found with aripiprazole use (DeLeon et al. 2004; Han et al. 2009; Snyder et al. 
2015). 
 
2.2.1.5 Prescription and Use of APDs in Childhood/Adolescence 
The prescription and use of APDs in children and adolescents is exponentially 
increasing worldwide (Olfson et al. 2006; Danielyan et al. 2007; Rani et al. 2008; 
Varley and McClellan 2009; Egger 2010; Olfson et al. 2010; Alexander et al. 2011; 
Olfson et al. 2012; Seida et al. 2012; Hoekstra 2014; Karanges et al. 2014), reported to 
have doubled in the UK (Haw and Stubbs 2007; Rani et al. 2008) and US (Alexander et 
al. 2011; Olfson et al. 2012; Hoekstra 2014; Karanges et al. 2014; Memarzia et al. 2014) 
over 10 year periods up to 2005 and 2010 respectively. In Australia, 
childhood/adolescent APD prescriptions (< 14 years) were found to be relatively stable 
in the 4 year period to 2007 (around approx. 0.25 dispensed drug utilisation/1000 
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population/day), however strong trends towards increases is becoming more apparent in 
recent years (Hollingworth et al. 2013; Karanges et al. 2014).  
 
Whilst first generation APDs (e.g. haloperidol) have been used in the treatment of 
various childhood mental illnesses since the 1970s, they were seen to exhibit a moderate 
treatment efficacy (Zuddas et al. 2011) whilst eliciting serious EPS. Second  generation 
APDs (including aripiprazole, olanzapine and risperidone) however were perceived to 
have a higher safety profile and treatment efficacy in the adolescent population,  leading 
to substantial increases in its prescription and use (Findling et al. 2005; Vitiello et al. 
2009; Zuddas et al. 2011) in the treatment of various childhood disorders; from mental 
illnesses including anxiety, depression and child-onset schizophrenia (Olfson et al. 
2010; Memarzia et al. 2014; Schneider et al. 2014), to various behavioural disorders 
(Findling et al. 2005; Haw and Stubbs 2007; Vitiello et al. 2009; Loy et al. 2012; 
Sharma and Shaw 2012). 
 
Furthermore, investigations into this growing trend of APD use in childhood/adolescent 
populations has found it to be mostly through off-label prescriptions (Cheng-Shannon et 
al. 2004; Haw and Stubbs 2007; Alexander et al. 2011; Olfson et al. 2012; Milstein et 
al. 2013; Hoekstra 2014; Larkin et al. 2014; Lòpez-De Fede et al. 2014; Schneider et al. 
2014). With governing bodies only approving the use of drugs over a specific age and 
for the treatment of a specific illness (e.g. risperidone, >5yrs for autism spectrum 
disorder)(Lòpez-De Fede et al. 2014), all childhood/adolescent prescriptions for APDs 
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outside this licenced age group and treatment purpose is deemed to be off-label use 
(Cote and E. 1996; Patel et al. 2005; Cooper et al. 2006; Haw and Stubbs 2007).  
 
Although APD use has some benefits in the treatment of mental and behavioural 
disorders in the childhood/adolescent period (Loy et al. 2012), there is a lack of 
substantial scientific evidence on the safety and efficacy during this critical 
neurodevelopmental phase over both a short and long-term period (Andersen and 
Navalta 2004; Cheng-Shannon et al. 2004; Loy et al. 2012; Memarzia et al. 2014; Xu et 
al. 2015). Detrimental side-effects including weight gain and EPS have currently been 
reported, and furthermore, there is the potential for long-term alterations to NT 
pathways including DA and 5-HT, critical to both the therapeutic efficacy of APDs, 
along with brain development and functioning (Crews et al. 2007; Correll 2008; Kumra 
et al. 2008; Almandil et al. 2013; Memarzia et al. 2014; Schneider et al. 2014).  
 
 
 The Dopamine Neurotransmitter System: Its Role in 2.2.2
Behaviour, Mental Illness & Potential Long-term Effects 
of Childhood Adolescent Antipsychotic Drug Use  
2.2.2.1 DA: Synthesis, Release and Re-uptake 
The DA NT is produced in several areas of the brain, including the substantia nigra 
(SN) and ventral tegmental area (VTA), with projections to various cortical (e.g. 
prefrontal cortex (PFC)) and sub-cortical (e.g. caudate putamen (CPu), nucleus 
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accumbens (NAc), hippocampus) regions of the brain (Figure 1). The synthesis, release 
and re-uptake of DA is demonstrated in Figure 2. DA biosynthesis begins by the 
hydroxylation of the amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (DOPA) 
via the enzyme tyrosine hydroxylase (TH) (Cooper et al. 1996). This initial phase is the 
rate limiting step in the synthesis of DA, with the activation of the TH enzyme the 
results of phosphorylation by a variety of protein kinases at multiple serine residues on 
the regulatory domain of TH. This phosphorylation of TH  produces the 
phosphorylated-tyrosine hydroxylase (p-TH) enzyme (Haycock 1990; Fitzpatrick 1999), 
with both the TH and p-TH enzymes well-known indicators of the synthesis levels of  
DA. The produced DOPA then undergoes decarboxylation by aromatic L-amino acid 
decarboxylase (AADC) (Cooper et al. 1996). Following synthesis, DA is then 
transported via the vesicular monoamine transporter 2 (VMAT2) into vesicles, which 
are then released into the synapse in response to a presynaptic action potential (Cooper 
et al. 1996; Eiden et al. 2004). Following transmission of the signal, the remaining DA 
in the synaptic cleft is re-absorbed via the dopamine active transporter (DAT) for 
recycling (Cooper et al. 1996; Masson et al. 1999). 
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The transmitted DA is the primary endogenous ligand for DA receptors, which are 
seven transmembrane domain G-protein coupled receptors (Missale et al. 1998; 
Beaulieu and Gainetdinov 2011). There are 5 DA receptor subtypes (D1 receptor to D5 
receptor), of which are divided into 2 groups; the D1-like family and the D2-like family. 
The D1-like family if of DA receptors consists of the D1 and D5 receptor subtypes, and 
Figure 1 - The four major Dopaminergic Pathways of the Brain & Associated 
Functions.  
(1) Nigrostriatal Pathway, (2) Mesolimbic Pathway, (3) Mesocortical Pathway, (4) Tuberoinfundibular 
Pathway.  
Adapted from Kobayashi 2001; Nasrallah 2009 
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are coupled to the Gαs/olf, which is linked to adenylate cyclise activation and subsequent 
increased intracellular concentration levels of the important second messenger cyclic 
adenosine monophosphate (cAMP). The D2-like family consists of the D2, D3 and D4 
DA receptor subtypes, which are coupled to the G-protein Gαi, which is linked to the 
inhibition of adenylate cyclise, and hence decreased intracellular concentration levels of 
cAMP (Missale et al. 1998; Neves et al. 2002; Girault and Greengard 2004; Beaulieu 
and Gainetdinov 2011). Furthermore, the DA D2 receptor subtype has subsequently 
been found to be expressed in 2 separate forms (D2-short chain and D2-long chain), with 
differing functions. D2-short chain receptors have been found pre-synaptically with 
modulatory functions, whilst D2-long chain receptors have been found to act and 
function as classical post-synaptic receptors (Khan et al. 1998). Both DA D1 and D2 
receptor subtypes have been found in abundance in the striatal and NAc regions of the 
brain, and are up to 100 times more abundant than the D3 to D5 receptor subtypes 
(Sokoloff and Schwartz 1995; Missale et al. 1998; Hurley and Jenner 2006). Whilst the 
DA D2 receptor is of particular interest as it is a high affinity target in the mechanism of 
APD action, both the DA D1 and D2 receptors have a clear role in shaping the 
dopaminergic signal.   
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Figure 2 – The synthesis, release and reuptake of Dopamine (DA) 
Abbreviations: AADC - Aromatic L-amino acid decarboxylase; D1R - Dopamine 1 receptor; D2R - 
Dopamine 2 receptor; D2 autoreceptor - Dopamine 2 autoreceptor; DA - Dopamine; DAT - Dopamine 
Active Transporter; DOPA - L-3,4-dihydroxyphenylalanine; p-TH - Phosphorylated Tyrosine 
Hydroxylase; TH - Tyrosine Hydroxylase; VMAT2 - Vesicular Monoamine Transporter 2.  
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2.2.2.2 Regulation of DA Synthesis and Release 
As mentioned in Section 2.2.2.1, following the synthesis and release of the DA NT into 
the synapse for binding with DA receptors, the re-uptake of any excess DA in the 
synaptic cleft occurs (Schmitz et al. 2003; Lyon et al. 2011; Miyake et al. 2011). This 
re-uptake process is part of the complex and highly regulated dopaminergic system, 
where the DAT and DA D2 autoreceptors interact in order to modulate the synthesis and 
production of DA, and hence in effect helping to shape DA signalling (Schmitz et al. 
2003). 
 
Whilst the system that regulates the production and transmission of DA is highly 
complex, studies have found a clear role of both the DAT and DA D2 autoreceptor in 
the modulation of dopaminergic neurotransmission. While DAT performs the action of 
DA re-uptake/reabsorption, the DA D2 autoreceptor has been found to regulate the 
dopaminergic NT via complex feedback systems at the soma and axon terminal 
(Schmitz et al. 2003). Activation of the D2 autoreceptor has been linked to numerous 
‘regulatory steps’ in the synthesis and release of DA, including eliciting 
hyperpolarization of the membrane, which subsequently decreases NT firing rate via the 
activation of potassium (K
+
) ion channels, and thus the modulation of TH synthesis (the 
rate-limiting step in DA NT production; Section 2.2.3.1) (O'Hara et al. 1996; Cathala 
and Paupardin-Tritsch 1999; Schmitz et al. 2003). Finally, a role of 5-HT receptors 
(including the 5-HT1 and 5-HT2 receptor classes) on the regulation/modulation of the 
DA signal has also been uncovered, with a presence of 5-HT receptors in nigrostriatal, 
mesolimbic and mesocortical pathways found to act in a either a facilitative (e.g. 5-
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HT1A and 5-HT2A receptors) and inhibitory (5-HT2C receptor) manner, shaping the 
overall DA signal (Alex and Pehek 2007) (see Section 2.2.3.2). 
 
2.2.2.3 The DA Pathways and its Role in the Pathogenesis of 
Mental Illness 
There are 4 major dopaminergic pathways in the brain, demonstrated in Figure 1. They 
are (1) the nigrostriatal pathway – extending from the SN to the CPu of the striatum, 
and found to play critical roles in processes including motor control; (2) the mesolimbic 
pathway – projecting from the VTA to the NAc, amygdala and hippocampus, and 
involved in the feeling of reward and desire; (3) the mesocortical pathways – from the 
VTA to the PFC, and involved in memory and emotional responses; and (4) the 
tuberoinfundibular pathway – extending from the arcuate nucleus of the hypothalamus 
to the median eminence of the pituitary gland, and is involved in hormonal regulation 
and sensory processes (Kobayashi 2001). Furthermore, studies have indicated a further 
role for the nigrostriatal pathway (extending from the SN to the CPu) in the motor 
control based side-effects of non-selective DA D2 receptor antagonist APDs (e.g. EPS) 
(Stephen and Stahl 2003). 
 
Neurotransmission along the mesolimbic, mesocortical and nigrostriatal pathways are of 
particular interest in regard to their involvement in the pathophysiology of mental 
illness (Carlsson 1988; Kapur and Mamo 2003; Kegeles et al. 2010; Howes et al. 2012; 
Purves-Tyson et al. 2012). Projections along the mesolimbic and mesocortical pathways 
especially have been found essential to the mediation of behaviour, anxiety and working 
memory (Grace 2000; Goto and Grace 2005; Grace et al. 2007). In particular, the NAc 
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has been found to be somewhat of a convergence centre of neurotransmission 
projections from the VTA, hippocampus and PFC. Furthermore, an alteration to these 
dopaminergic projections via DA D1 receptor and D2 receptor (from the hippocampus 
and PFC respectively) to the NAc results in an instability of the DA system, disrupting 
the tonic (facilitating D2 receptor activation from the PFC) and phasic (facilitating D1 
receptor activation from the hippocampus) DA neurotransmission  (Grace 2000; Goto 
and Grace 2005; Grace et al. 2007). Any disruptions to DA neurotransmission, such as 
through APD use, has been found to be fundamental to the pathophysiology of major 
mental illnesses such as schizophrenia (Csernansky and Bardgett 1998; Meyer-
Lindenberg et al. 2002; Goto and Grace 2005; Grace et al. 2007). Therefore, an 
undisrupted and highly regulated synthesis of DA, along with a balanced transmission 
from DA neurons in the VTA, PFC and hippocampus to the NAc may assist in the 
alleviation of some behavioural, anxiety and working memory issues affecting those 
with various mental illnesses. 
 
2.2.2.4 Potential Long-term Effects of Early APD Use on the DA 
NT System 
As mentioned in Section 2.2.1.1, APDs are known to predominantly produce their 
therapeutic effects through a mechanism of action concentrated around DA receptors, 
specifically the D2 receptor subtype, to modulate the DA signal in mesolimbic, 
mesocortical and nigrostriatal pathways (Grace et al. 2007; Kegeles et al. 2010; Purves-
Tyson et al. 2012). Although relatively unknown in the clinical setting, there is growing 
evidence through animal studies that juvenile treatment with APDs for a period of up to 
4 weeks has the potential to elicit long-term permanent changes to the DA NT system, 
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including alterations to synthesis markers (TH & p-TH), transporter (DAT) and DA D1 
and D2 receptor distribution and density levels (Moran-Gates et al. 2006; Der-Ghazarian 
et al. 2010; Vinish et al. 2012; Xu et al. 2012; Milstein et al. 2013; Klomp et al. 2014; 
Varela et al. 2014; Lian et al. 2016; Moe et al. 2016). Whilst numerous short-term 
investigations have found that early APD treatment for 1-4 weeks can result in various 
immediate changes to the aforementioned features of the DA system (Moran-Gates et 
al. 2006; Varela et al. 2014; Lian et al. 2016), studies into the longer term effects into 
adulthood (where a 4 week treatment period in adolescence is utilised) are lesser in 
number (Vinish et al. 2012; Milstein et al. 2013). Although investigations have 
uncovered changes to the density and distribution of DA receptors (including D1 and D2 
receptors), there is limited evidence on the long term effects on the production and 
regulation of the DA signal along dopaminergic pathways. 
 
2.2.2.4.1 The DA D1 receptor, mental illness and the therapeutic 
efficacy of APDs 
The DA D1 receptor is expressed throughout the brain, however the highest receptor 
density levels are found in nigrostriatal, mesolimbic and mesocortical areas (Missale et 
al. 1998; Beaulieu and Gainetdinov 2011). In particular, brain regions including the 
PFC, CPu, NAc, SN and amygdala have been found to express the highest D1 receptor 
levels, whilst lower levels have been found in hippocampal and hypothalamic brain 
regions. As mentioned in Section 2.2.2.1, the D1 receptor is a G-protein coupled 
receptor found exclusively on the post-synaptic cleft of DA receptive cells, with its 
activation following the phasic release of the DA signal known to play a critical role in 
working memory, particularly in cortical brain regions (Aultman and Moghaddam 2001; 
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Milstein et al. 2013), and the regulation of DA transmission along DA pathways (Grace 
2000; Goto and Grace 2005; Grace et al. 2007).  
 
Although second generation APDs including aripiprazole, olanzapine and risperidone 
are known to elicit their therapeutic effects predominantly through high affinity actions 
on the DA D2 receptor (with a low affinity for the D1 receptor), investigations have 
uncovered decreases to D1 receptor density levels in the NAc and cortical regions 
following APD treatment in young animals. Specifically, APD treatment with 
olanzapine and clozapine in young animals over a short-term period have resulted in 
immediate decreases to D1 receptor density levels (Moran-Gates et al. 2006; Lian et al. 
2016), whilst long-term treatment has resulted in long-term decreases (Vinish et al. 
2012; Milstein et al. 2013) in male rats. With the D1 receptor known to play a key role 
in the regulation of the DA signal, APDs targeting the D1 receptor may play a key role 
in the therapeutic effects of APDs and the alleviation of the symptomology of mental 
illness. 
 
2.2.2.4.2 The DA D2 receptor, mental illness and the therapeutic 
efficacy of APDs 
The DA D2 receptor is known to be located throughout the brain, with varying receptor 
density levels. Investigations have found the highest levels in the NAc, striatum and 
olfactory tubercle, whilst they are also expressed at significant densities throughout 
cortical, hippocampal, SN, VTA, hypothalamic, amygdala and septal brain regions 
(Missale et al. 1998; Seeman 2006; Beaulieu and Gainetdinov 2011). As specified in 
Section 2.2.2.1, the DA D2 receptor is a G-protein coupled receptor known to be found 
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in both short-form (as a pre-synaptic autoreceptor), and long-form (as a traditional post-
synaptic receptor)(Khan et al. 1998). Its activation is linked to the Gαi/o class of G-
proteins, known to induce inhibition of adenylate cyclase and decreased secondary 
messenger signalling (Neves et al. 2002; Girault and Greengard 2004; Beaulieu and 
Gainetdinov 2011). 
 
Previous studies have accumulated undoubted evidence of the critical role the DA D2 
receptor plays in the pharmacological efficacy of first and second generation APD 
treatment (Meltzer 2002; Nasrallah 2008; Kegeles et al. 2010). As mentioned 
previously, APDs including risperidone and olanzapine are known to have a high 
affinity, antagonist mechanism of action on the DA D2 receptor, with their therapeutic 
benefits seen around a 60-85% receptor occupancy rate, however detrimental movement 
and metabolic side effects were also clearly apparent (Lieberman 2004; Seeman 2011; 
Ginovart and Kapur 2012). The introduction of the APD aripiprazole however saw an 
enhanced therapeutic efficacy in patients with a decrease in detrimental side effects. 
Studies into the pharmacology of aripiprazole revealed a critical role of its high affinity 
(see Table 1), high receptor occupancy (above 90%), partial agonist mechanism of 
action on the DA D2 receptor in the regulation of the DA signal, and subsequent 
alleviation of some symptomology of mental illness (Burris et al. 2002; Shapiro et al. 
2003; DeLeon et al. 2004; Wood and Reavill 2007; Etievant et al. 2009; Natesan et al. 
2011). A combined vital role of the partial agonist actions of aripiprazole on the 5-HT1A 
and 5-HT2C receptors and antagonist actions on the 5-HT2A receptor and correlation to 
therapeutic efficacy was also found (Kapur and Remington 1996; Kusljic et al. 2003; 
Seo et al. 2008).  
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2.2.2.5 The Role of the DA System in Behavioural Attributes & 
Potential Effects of Early APD Treatment 
The DA NT system has also been found to play a role in multiple behavioural attributes, 
with alterations to the production/synthesis, transport and binding of DA in cortical, 
striatal and ventral tegmental brain regions directly linked to changes to various 
behavioural attributes (Kelly et al. 1975; Karl et al. 2006; de Oliveira et al. 2009; 
Beaulieu and Gainetdinov 2011; Biojone et al. 2011). Changes to behaviours including 
locomotor activity levels, social interaction, depressive- and anxiety-like behaviours 
have all previously been linked to alterations in the DA NT system, with increases to 
DA signalling and receptor density levels in areas of the brain including the PFC, NAc 
and VTA correlated with decreases to anxiety and depressive-like behaviours (Karl et 
al. 2006; de Oliveira et al. 2009; Adriani et al. 2010; Biojone et al. 2011), and increased 
locomotor levels (Seo et al. 2008; Beaulieu and Gainetdinov 2011).  
 
With short and long-term APD treatment in juvenile rodents known to have the 
potential to elicit immediate and long-term changes to DA receptor density levels and 
DA neurotransmission (Moran-Gates et al. 2006; Vinish et al. 2012; Milstein et al. 
2013; Varela et al. 2014), there is the subsequent potential for early treatment with 
APDs to significantly influence numerous behavioural attributes.   
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 The Serotonin Neurotransmitter System: Its Role in 2.2.3
Behaviour, Mental Illness & Potential Long-term Effects 
of Childhood Adolescent Antipsychotic Drug Use 
2.2.3.1 5-HT: Synthesis, Release and Re-uptake 
The 5-HT NT is one of the major monoaminergic NTs in the brain, responsible for 
signal transduction between 5-HT neurons (Silber and Schmitt 2010). Predominantly 
produced in neurons located in the Raphe Nucleus (RN) of the midbrain (where the 
majority of 5-HT neurons are located), 5-HT projects throughout the brain including the 
cortex, striatum and hippocampus, with brain regions including the SN and NAc 
innervated by projections from the RN (Dawson 1999; Kusljic et al. 2003; Müller and 
Jacobs 2010; Beliveau et al. 2017; Wong-Lin et al. 2017).  
 
The process of 5-HT synthesis, release and re-uptake is shown in Figure 3, and begins 
with the conversion of the amino acid tryptophan to 5-hydroxytryptophan (5-HTP) via 
tryptophan hydroxylase (Dawson 1999), an enzyme that is synthesized in 5-HT neurons 
in the RN and is the sole precursor and rate limiting step in the production of the 5-HT 
NT (Dawson 1999; Richard et al. 2009). The conversion of 5-HTP to 5-HT then occurs 
via the decarboxylation of 5-HTP by the enzyme AADC, the same enzyme present in 
the synthesis of DA from DOPA (see Section 2.2.2.1) and found to be located in both 
serotonergic cells in the RN and catecholaminergic cells in relevant brain regions 
(Dawson 1999). The synthesised 5-HT is then transported via vesicular monoamine 
transporters and released into the synapse, triggered by 5-HT cell firing rate from the 
RN (Dawson 1999). Following transmission of the 5-HT signal, termination of potential 
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synaptic effects are controlled through the binding of 5-HT to the 5-HT transporter (5-
HTT), located on pre-synaptic neurons and enables recycling of the 5-HT signal and 
hence concentration in the synaptic cleft (Dawson 1999).  
 
Figure 3 - The synthesis, release and reuptake of Serotonin (5-HT) 
Abbreviations: 5-HT1A - Serotonin 1A receptor; 5-HT1A autoreceptor - Serotonin 1A autoreceptor; 
5-HT2A - Serotonin 2A receptor; 5-HT2C - Serotonin 2C receptor; 5-HT - Serotonin; 5-HTP - 5-
hydroxy-L-tryptophan; 5-HTT - Serotonin transporter; AADC - Aromatic L-amino acid 
decarboxylase; TPH - Tryptophan Hydroxylase; VMAT - vesicular monoamine transporter.  
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Michael De Santis  31 
 
 
A monoamine NT, the effects of 5-HT are known to be mediated by approximately 
fourteen distinctively dissimilar 5-HT receptor subtypes, categorised into seven 
different classes based on their structural and operational characteristics (5-HT1-5-HT7) 
(Barnes and Sharp 1999; Fink and Göthert 2007; Hannon and Hoyer 2008; Meltzer and 
Huang 2008; Beliveau et al. 2017). Whilst the vast majority of 5-HT receptor classes 
are G-protein coupled receptors (5-HT1-2, 5-HT4-7) and linked to secondary messenger 
systems & subsequent modulatory effects (Araneda and Andrade 1991; Wong-Lin et al. 
2017), the 5-HT3 class has been identified as a ligand-gated ion channel and subsequent 
excitatory postsynaptic potential (see Table 2) (Barnes and Sharp 1999; Wong-Lin et al. 
2017). Of particular interest are the 5-HT1A and 5-HT2A and 5-HT2C receptor subtypes 
that are known to be widespread throughout the brain and play opposing modulatory 
functions (see Sections 2.2.3.4.1, 2.2.3.4.2 and 2.2.3.4.3), and furthermore have been 
heavily implicated in both the pathology and treatment of various mental illnesses 
(Araneda and Andrade 1991; Meltzer and Massey 2011; Beliveau et al. 2017; Carhart-
Harris and Nutt 2017; Wong-Lin et al. 2017).  
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Table 2 – Profile of 5-HT receptor classes & associated G-protein & secondary 
messenger system 
Receptor 
class 
Class Subtypes Associated  
G-protein 
Secondary 
Messenger/Signal 
Transduction 
5-HT1 5-HT1A, 5-HT1B, 5-HT1D, 
5-HT1E, 5-HT1F 
Gαi/Gαo cAMP, PKA / ↓ 
5-HT2 5-HT2A, 5-HT2B,  
5-HT2C 
Gαq PLC, IP3, DAG, PKC / ↑ 
5-HT3 5-HT3 Ion Channel Ligand-gated Ion Channel 
5-HT4 5-HT4 Gαs cAMP, PKA / ↑ 
5-HT5 5-HT5A, 5-HT5B Gαi/Gαo cAMP / ↓ 
5-HT6 5-HT6 Gαs cAMP, PKA 
5-HT7 5-HT7 Gαs cAMP, PKA 
Abbreviations: 5-HT- 5-hydroxytryptamine (serotonin); cAMP- cyclic adenosine 
monophosphate; DAG- diacylglycerol; IP3- inositol 1,4,5-triphosphate; PKA- protein kinase A; 
PKC- protein kinase C;  PLC- phospholipase C  
(Barnes and Sharp 1999; Fink and Göthert 2007; Hannon and Hoyer 2008; Wong-Lin et al. 
2017) 
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2.2.3.2 Regulation of 5-HT Synthesis and Re-uptake 
As indicated in Section 2.2.3.1, the regulation of the synthesis and release of 5-HT into 
the synaptic cleft for binding with 5-HT receptors is regulated through both presynaptic 
autoreceptors and the 5-HTT (Dawson 1999; Alex and Pehek 2007; Fink and Göthert 
2007). Both the 5-HT1A and 5-HT1B/D receptor subtypes are well-known to also be 
located presynaptically in the RN where they function as autoreceptors, with the 5-HT1A 
autoreceptor located on the cell body of the 5-HT neuron, and 5-HT1B/D autoreceptors 
located on nerve terminals. Upon the release of 5-HT somatodendritically, 5-HT1A 
autoreceptor activation inhibits further 5-HT cell firing (Alex and Pehek 2007), and 
combined with the 5-HTT, which facilitates the re-uptake of excess 5-HT in the 
synaptic cleft, they act as feedback systems to regulate and modulate the production and 
transmission of the 5-HT signal (Blier and Ward 2003; Kish et al. 2005; Alex and Pehek 
2007; Fink and Göthert 2007).  
 
Furthermore, in addition to the regulation of the 5-HT signal itself, previous studies 
have demonstrated that the highly interconnected networks of 5-HT projections may 
also play a critical role in the autoregulation of other NT systems, including glutamate, 
gamma-aminobutyric acid (GABA) and DA (Lemos et al. 2006; Bang et al. 2012; 
Wong-Lin et al. 2017). In particular, a significant involvement of 5-HT receptors in the 
modulation of DA in mesolimbic, mesocortical and nigrostriatal pathways has been 
highlighted (Kapur and Remington 1996; Alex and Pehek 2007). With 5-HT neurons 
known to project from the RN to multiple dopaminergic regions of the brain, different 
5-HT receptor subtypes have subsequently been found to affect dopaminergic function 
in different ways.  
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2.2.3.3 Serotonergic Projections and its Role in the Pathogenesis 
of Mental Illness 
As mentioned previously, 5-HT neurons are known to be predominantly located in the 
RN of the midbrain, and project through the majority of the brain including the cortex, 
striatum, hippocampus and SN (Wilson and Molliver 1991; Dawson 1999; Kusljic et al. 
2003; Müller and Jacobs 2010; Beliveau et al. 2017; Wong-Lin et al. 2017). Whilst 
investigations have found that the 5-HT NT plays a key role in various sensory and 
motor processes in the central nervous system (CNS) (Carlsson 1987; Tecott et al. 1995; 
Sawa and Snyder 2002; Carlsson et al. 2004; Dolžan et al. 2008), there is growing 
evidence of its involvement in the pathophysiology of various mental illnesses and 
behavioural attributes, including schizophrenia, anxiety and depression (Kusljic et al. 
2003; Carlsson et al. 2004; Matsumoto et al. 2005; Dolžan et al. 2008; Seo et al. 2008; 
Meltzer 2012; Teissier et al. 2015).  
 
The link between the 5-HT NT system and the physiology of numerous mental illnesses 
has also been found to be multi-faceted, with investigations also uncovering a clear 
negative correlation between the pharmacological actions on and alterations to 5-HT 
receptors and signal (including 5-HT1A and 5-HT2A receptors), and the modulation of 
the DA signal and NT system functioning (Kapur and Remington 1996; Abi-Dargham 
et al. 1997; Horacek et al. 2006; Alex and Pehek 2007; Seo et al. 2008) as indicated in 
Section 2.2.3.2. Specifically, actions on 5-HT receptors in cortical, striatal and 
hippocampal brain regions has been found critical to the ability of APDs to modulate 
the DA signal (Meltzer and Huang 2008; Kusumi et al. 2015), with 5-HT receptor 
subtypes including the 5-HT1A and 5-HT2A receptor found to facilitate the release of DA 
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along mesocortical, mesolimbic and nigrostriatal pathways upon agonist and antagonist 
actions on them respectively. The 5-HT2C receptor subtype has also demonstrated the 
capability to regulate the DA signal, with inhibitory effects on DA release upon both 
agonist actions on the receptor and also in phasic periods due to high levels of 
constitutive activity. Whilst the 5-HT2C receptor has been found to modulate DA release 
through tonic inhibition from terminal regions of the mesolimbic and nigrostriatal 
pathways, studies have uncovered an ability of the PFC to produce similar effects in the 
mesocortical DA pathway (Kapur and Remington 1996; Abi-Dargham et al. 1997; 
Kusljic et al. 2003; Alex and Pehek 2007). With alterations to the DA signal/DA NT 
system in mesocortical, mesolimbic and nigrostriatal pathways correlated to the 
pathophysiology and thus treatment of various mental illnesses (see Section 2.2.2.3) 
(Carlsson 1988; Kapur and Mamo 2003; Kegeles et al. 2010; Howes et al. 2012; 
Purves-Tyson et al. 2012), the 5-HT NT system clearly has a significant role to play as a 
secondary/dual pharmacological target of APDs in modulating the DA signal and 
enhancing the therapeutic effects of treatment with decreased side effects. 
 
 
2.2.3.4 Potential Long-term Effects of Early APD Use on the 5-HT 
NT System 
With the enhanced therapeutic efficacy of second generation APDs, attention turned to 
the importance of the 5-HT system in the pharmacological treatment of mental illnesses 
(Meltzer et al. 2003; Meltzer and Massey 2011; Amato 2015). Investigations into the 
pharmacology of second generation APDs quickly uncovered a relatively lower 
antagonistic effect on the DA D2 receptor and 5-HT1A receptor, and higher affinity for 
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the 5-HT2A and 5-HT2C receptor subtypes, with the functional interaction between the 5-
HT and DA systems resulting in the modulation of the DA signal and hence an 
alleviation of symptomology with decreased side effects (Kapur and Remington 1996; 
Abi-Dargham et al. 1997). 
 
As indicated in Section 2.2.2.4, with the aforementioned exponential increases in the 
prescription and use of APDs in the juvenile population, there is growing evidence that 
treatment during such a critical time of neurodevelopment may cause long-term 
alterations to the functioning of the 5-HT NT system. Studies have uncovered that early 
APD treatment may result in immediate alterations to both the density of 5-HT 
receptors (in particular increases to 5-HT1A, and decreases to 5-HT2A and 5-HT2C 
receptors following treatment with APDs including olanzapine and risperidone), and 
also the production and transmission of the 5-HT NT signal (Maciag et al. 2006; Choi et 
al. 2010; Choi et al. 2012; Klomp et al. 2012; Klomp et al. 2014; Lian et al. 2016; Choi 
et al. 2017). Although current investigations into the effects of short-term APD 
treatment on the 5-HT1A, 5-HT2A and 5-HT2C receptors have uncovered various 
immediate alterations to the density/distribution of 5-HT receptors (Moran-Gates et al. 
2006; Varela et al. 2014; Lian et al. 2016; Choi et al. 2017), the long-term effects 
following an early treatment period is currently unknown. 
 
2.2.3.4.1 The 5-HT1A receptor, mental illness and the therapeutic 
efficacy of APDs 
The 5-HT1A receptor is a G-protein coupled receptor, found to be most highly expressed 
in the RN and limbic brain regions, including the hippocampus, as well as cortical areas 
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(Barnes and Sharp 1999; Hannon and Hoyer 2008; Amato 2015). As mentioned in 
Sections 2.2.3.1 and 2.2.3.2, 5-HT1A receptors are well-known to be located both post-
synaptically to 5-HT neurons acting as a normal post-synaptic receptor, and also pre-
synaptically on the cell body of 5-HT neurons in the RN where they act as an 
autoreceptor, modulating the 5-HT signal via inhibition of 5-HT cell firing (Kapur and 
Remington 1996; Barnes and Sharp 1999; Blier and Ward 2003; Alex and Pehek 2007; 
Hannon and Hoyer 2008). Investigations into the functional processes involved in the 
modulatory role of 5-HT1A on the 5-HT NT system have found that 5-HT1A receptor 
agonism/activation has an antagonist effect on 5-HT2A receptors (Meltzer et al. 2003), 
which subsequently decreasing 5-HT function (Alex and Pehek 2007). In addition to its 
modulatory effects on the 5-HT NT system, 5-HT1A receptors have also been found to 
play an important role in the regulation of DA release in areas of the brain including the 
PFC, CPu, NAc, hippocampus, SN and VTA (see Section 2.2.3.2) (Kapur and 
Remington 1996; Meltzer et al. 2003; Alex and Pehek 2007).  
 
With alterations to DA signalling in mesocortical and mesolimbic pathways correlated 
to the appearance of multiple features of mental illness symptomology, this has resulted 
in the 5-HT1A receptor being identified as a pivotal target for APD treatment and the 
alleviation of mental illness symptomology (Rollema et al. 1997; Ichikawa et al. 2001; 
Li et al. 2004). Correlating with advancements in second generation APD treatment has 
been an increased affinity and partial agonist mechanism of action to the 5-HT1A 
receptor (Shapiro et al. 2003; DeLeon et al. 2004; Newman-Tancredi et al. 2005; Mamo 
et al. 2007; Correll 2010; Mailman and Murthy 2010; de Bartolomeis et al. 2015), as 
one part of a combined pharmacology for both DA (in particular the D2 receptor) and 5-
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HT (in particular the 5-HT1A, 5-HT2A and 5-HT2C receptors) receptor subtypes (Mamo 
et al. 2007; Wood and Reavill 2007).  
 
Whilst the majority of previous investigations into the effects of APD treatment on 5-
HT1A receptors have shown no alterations, some studies into the immediate effects of 
treatment of up to 3 weeks in juvenile rats have found that APDs including clozapine, 
olanzapine and risperidone has the potential to increase 5-HT1A receptor levels in areas 
of the brain including the PFC and hippocampus (Choi et al. 2010; Choi et al. 2017). 
Investigations into the adult cohort have found even lesser effects of APD treatment, 
with a small number of studies over identical treatment periods finding immediate 
increases to 5-HT1A receptor binding in the PFC of tested animals (Tarazi et al. 2002; 
Choi et al. 2017). 
 
2.2.3.4.2 The 5-HT2A receptor, mental illness and the therapeutic 
efficacy of APDs 
The 5-HT2A receptor is a G-protein coupled receptor found to be most highly expressed 
in 5-HT terminal regions of the brain including the CPu, NAc, hippocampus and PFC 
(Barnes and Sharp 1999; Alex and Pehek 2007; Amato 2015), with lower density levels 
also uncovered on the cell bodies of DA neurons in the SN and VTA (Jakab and 
Goldman-Rakic 1998; Doherty and Pickel 2000; Alex and Pehek 2007) and cortical 
GABAergic and cortico-striatal glutamatergic neurons (Choi et al. 2017). Primarily 
known as a post-synaptic receptor, stimulation of the receptor has been linked to an 
enhanced intracellular molecular signal-transduction cascade and thus 5-HT signal, with 
conversely, antagonism of the 5-HT2A receptor seen to result in decreased 5-HT 
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function (Alex and Pehek 2007; Fink and Göthert 2007). Furthermore, as described in 
Section 2.2.3.3, actions on the 5-HT2A receptor have also been linked to changes in the 
DA signal across mesocortical, mesolimbic and nigrostriatal pathways, with activation 
of the 5-HT2A receptor resulting in an increase to DA activity (Alex and Pehek 2007). 
Furthermore, small density levels of the 5-HT2A receptor have also been found pre-
synaptically in cortical brain regions, and thus a potential regulatory role is possible yet 
still to be confirmed (Miner et al. 2003; Alex and Pehek 2007). 
 
With the enhanced therapeutic efficacy and lowered side effects of second generation 
APD use, the change in pharmacology to a higher affinity for the 5-HT2A receptor and 
lesser affinity for the DA D2 receptor was highlighted as having a key role in these 
advancements in treatment (Kusumi et al. 2000; Horacek et al. 2006; Meltzer and 
Massey 2011). Although there are no current investigations into the long-term effects of 
early APD treatment on the density of 5-HT2A receptors in the adult brain, some recent 
studies into the immediate effects of treatment with second generation APDs including 
olanzapine and risperidone on both young and adult rodents have all demonstrated a 
capability to decrease 5-HT2A density levels across cortical and brain regions (Tarazi et 
al. 2002; Choi et al. 2010; Lian et al. 2016; Choi et al. 2017) 
 
2.2.3.4.3 The 5-HT2C receptor, mental illness and the therapeutic 
efficacy of APDs 
The 5-HT2C receptor is known to have a similar pharmacological profile, structure and 
secondary messenger systems to 5-HT2A receptors. Investigations into their distribution 
however have found them to be only located in the CNS, with highest density 
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populations found post-synaptically in the cortex, CPu, limbic system (including the 
NAc and hippocampus) and the SN, along with the striatum and VTA (Radja et al. 
1991; Rick et al. 1995; Alex and Pehek 2007; Amato 2015). As indicated previously, 
stimulation of the 5-HT2C receptor has a similar effect to the 5-HT2A receptor, with 
increases to secondary messenger signalling ultimately resulting in an enhanced 5-HT 
signal (Alex and Pehek 2007; Fink and Göthert 2007).  
 
Along with the 5-HT2A receptor, the 5-HT2C receptor has also been similarly linked to 
changes in the DA signal, and hence involved in the pathophysiology of various mental 
illnesses (as described in Section 2.2.3.3) (Meltzer and Huang 2008; Meltzer and 
Massey 2011). Unlike the 5-HT2A receptor, the 5-HT2C receptor has also been found to 
have an inhibitory effect on DA release both upon agonist actions on the receptor, and 
furthermore in phasic periods due to its high levels of constitutive activity(Alex and 
Pehek 2007). Unique to the 5-HT2C receptor in comparison to its 5-HT2A counterpart is 
this aforementioned higher level of constitutive activity (Berg et al. 2005), an attribute 
that may be a key factor in its relationship to both the pathophysiology of mental illness 
and as a pharmacological target of APD treatment.  
 
Although no previous studies have investigated the long-term effects of early APD on 
5-HT2C receptors in the adult brain, a small number of investigations into the immediate 
effects of treatment in both young (Lian et al. 2016) and adult (Tarazi et al. 2002; 
Huang et al. 2006; Lian et al. 2015) rodent models have been completed. Whilst 
immediate decreases to 5-HT2C receptor were found in brain regions including the PFC, 
NAc, CPu and hippocampus following treatment with olanzapine, a potentially role of 
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the 5-HT2C receptor in APD induced weight gain was also evident (Hannon and Hoyer 
2008; Sicard et al. 2010). 
 
2.2.3.5 The Role of the 5-HT System in Behavioural Attributes & 
Potential Effects of Early APD Treatment 
Along with the DA NT system, changes to the production, transmission and binding of 
5-HT from the dorsal RN and median RN to cortical and striatal brain regions has also 
been correlated to alterations in various behavioural attributes (Tanaka et al. 2007; 
Dalley et al. 2008; Choi et al. 2010; Young 2013; Teissier et al. 2015; Wong-Lin et al. 
2017). Alterations to the 5-HT NT system have uncovered associations to a range of 
mental illnesses and subsequent behavioural attributes, including reward, depression 
and anxiety levels (Millan 2004; Joca et al. 2007; Teissier et al. 2015; Wong-Lin et al. 
2017). Furthermore, whilst APDs such as aripiprazole, olanzapine and risperidone 
known to elicit antagonistic effects on 5-HT2A and 5-HT2C receptors and decrease 5-HT 
projections, the negative correlation and regulatory role of the 5-HT NT system on the 
DA NT system may therefore also be indirectly resulting in an effect on DA-linked 
behavioural attributes, including locomotor activity levels (see Section 2.2.2.5) (Kusljic 
et al. 2003; Seo et al. 2008). Specifically, previous investigations have linked decreases 
in 5-HT NT signalling and projections from the RN with decreased anxiety and 
depressive-like behaviours, and increases to activity levels (Kusljic et al. 2003; Seo et 
al. 2008; Biojone et al. 2011). 
 
With previous investigations clearly highlighting the potential of short and long-term 
APD treatment on 5-HT1A, 5-HT2A and 5-HT2C receptors to result in immediate and 
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long-term changes to both the density of receptors and the 5-HT signal (Mora et al. 
1997; Choi et al. 2017), there is the potential that this may result in long-term alterations 
to behavioural attributes linked to alterations to the 5-HT (and DA) NT systems, 
including anxiety and depressive behaviours, later in life. 
 
 
 Brain Development, the Dopamine and Serotonin 2.2.4
Neurotransmitter Systems & Potential Impact of APD 
Exposure 
2.2.4.1 Mammalian Neurodevelopmental Processes 
Investigations into the development of the mammalian brain have identified seven 
phases of neural development (see Table 3), with numerous critical maturational 
changes highlighted during the early postnatal phases all the way through to early 
adulthood (Andersen 2003; Andersen and Navalta 2004; Kolb et al. 2013). Comparative 
studies of the human and rodent brain have identified the time periods over which each 
of these neurodevelopmental phases occur, from early embryonic development and 
initial postnatal days through childhood/adolescence into the adult brain, with the 
adolescent period defined as the time encompassing the initial postnatal days through 
the most rapid phases of development (Stiles and Jernigan 2010; Kolb et al. 2013). A 
comparative overview of the neurodevelopmental process of the DA and 5-HT NT 
systems in rats and humans, from birth to adulthood, is outlined in Figure 4. 
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During the embryonic time period until birth, neural progenitor cells are known to 
develop, migrate and differentiate, before elimination of up to 50% occurs in the period 
immediately before birth (Andersen 2003). From birth and through the 
childhood/adolescent period, significant increases to synapse and receptor density levels 
to adult levels occurs, followed by a process of regressive elimination into adulthood 
until the brain reaches its mature topography (Andersen 2003) (see Figure 4).  
 
Monoamine NTs including DA and 5-HT have been identified as playing critical roles 
in the aforementioned development of NT producing neurons and target tissues 
Table 3 – Seven Stages of Brain Development 
Stage Process 
1 Neurogenesis & Gliogenesis 
2 Cell Migration 
3 Cell Differentiation  
4 Cell Maturation 
5 Synaptogenesis 
6 Cell Death & Synaptic Pruning 
7 Myelogenesis 
Adapted from (Stiles and Jernigan 2010; Kolb et al. 2013) 
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throughout the brain (Mazer et al. 1997; Andersen and Navalta 2004). Inclusive in this 
is the development of neurons that produce DA and 5-HT respectively, along with 
relevant receptor subtypes across both NT systems and in respective brain regions 
(Andersen and Navalta 2004). Previous investigations have highlighted these numerous 
maturational changes during this early post-natal period (McCutcheon and Marinelli 
2009), with the various phases of development within each NT typified by age-
dependent responses to the stimulation of various receptor subtypes and firing of 
respective neurons (Marinelli and White 2000; Tseng and O'Donnell 2007; Tseng and 
O'Donnell 2007; McCutcheon and Marinelli 2009). Specifically, investigations have 
uncovered significant increases to synapse and receptor density levels across both the 
DA and 5-HT NT systems into early stages of adulthood, followed by a period of 
regressive elimination (Dinopoulos et al. 1997; Andersen 2003; Andersen and Navalta 
2004). 
 
 
It is during the neurodevelopmental phase that differences between male and female 
sexes have also been identified (Andersen and Teicher 2000; De Bellis et al. 2001; 
Andersen 2003). Specifically, differences in the rate and age of myelination upon 
Figure 4 – Comparative timeline of human (below) and rat (above) brain 
development.  
Adapted from (Andersen and Navalta 2004) 
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comparison of sexes have been found, along with the differences between the rate and 
age of synapse and receptor production and elimination, including within both the DA 
and 5-HT NT systems (Andersen and Teicher 2000; Andersen 2003). 
 
2.2.4.2 The Trophic Role of the DA & 5-HT NT Systems in 
Neurodevelopment, and Potential Effects of Early APD 
Treatment 
Monoamine NT systems, including DA and 5-HT, have also been found to play a 
critical trophic role in the neurodevelopmental processes that shape the final 
functionality of the adult brain (Levitt et al. 1997; Mazer et al. 1997; Frost and Cadet 
2000; Whitaker-Azmitia 2001; Andersen 2003; Andersen and Navalta 2004; Marco et 
al. 2011; Klomp et al. 2012; Piontkewitz et al. 2012; Milstein et al. 2013; Cousins and 
Goodyer 2015). Studies have uncovered both NT’s significant, concentration-
dependent, trophic effect on the various phases of brain development; including the 
development of receptors, sprouting and formation of synapses and overall axonal 
growth (Kalsbeek et al. 1988; Lankford et al. 1988; Gelbard et al. 1990; Andersen and 
Navalta 2004; Lauder 2016). Specifically, decreases to the availability of endogenous 
DA and 5-HT NT levels in the early development phases following birth, and the 
subsequent lack of stimulation of receptor subtypes has been found to impact the 
development of receptors within each NT system, and the overall development and 
growth of neurites (Diefenbach et al. 1995; Dinopoulos et al. 1997; Whitaker-Azmitia 
2001; Andersen 2003; Andersen and Navalta 2004; Song et al. 2017). 
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The childhood/adolescent period in particular that has been highlighted as a critical 
phase for the aforementioned neurodevelopment, with numerous processes in which 
shape the final adult topography of the brain underway during this time of extreme flux 
(Andersen 2003; Andersen and Navalta 2004; Piontkewitz et al. 2012). During this 
period until final adult brain topography is reached, several factors have been identified 
as capable of influencing the functionality of the brain long-term (Levitt et al. 1997; 
Frost and Cadet 2000; Andersen 2003; Marco et al. 2011; Klomp et al. 2012; 
Piontkewitz et al. 2012; Milstein et al. 2013; Cousins and Goodyer 2015). Prescription 
and use of drugs such as APDs have been identified as having the potential to elicit 
long-term, permanent alterations to NT pathways throughout the brain during this 
developmental period (Andersen and Navalta 2004; Andersen 2005; Bock 2010; 
Andersen and Navalta 2011; Alcantara et al. 2014). With APDs known to have a high 
affinity for and produce their therapeutic effects through potent actions on receptors 
within the DA and 5-HT NT system, and with both NT systems known to undergo 
numerous critical neurodevelopmental processes and play a significant role in overall 
brain development during the childhood/adolescent period (see Section 2.2.4.1 above), 
there is the potential that drugs with pharmacological actions targeting these NT 
systems will impact their maturation in a process known as neuronal imprinting 
(Andersen 2003; Frost et al. 2010; Kolb et al. 2013; Bottelier et al. 2014). Limited 
studies however have thus far been completed to identify this capability for drug 
treatment during this critical neurodevelopmental phase to cause long-term alterations to 
the functionality of the DA and 5-HT NT systems across both sexes, (Moran-Gates et 
al. 2006; Vinish et al. 2012; Milstein et al. 2013), and forms the premise for this thesis.  
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2.3 Rationales, Aims and Hypotheses 
 Rationales of this thesis 2.3.1
As reviewed above, although there may be some short-term benefits of early APD 
prescription and use, there is the potential for widespread alterations to numerous NT 
systems, including the DA and 5-HT NT systems. APDs including aripiprazole, 
olanzapine and risperidone have a high affinity for, and produce their therapeutic effects 
through potent mechanisms of action on DA and 5-HT receptors, including DA D2 and 
5-HT2A and 5-HT2C receptor subtypes. With both the DA and 5-HT NT systems also 
known to undergo, and be involved in, numerous critical neurodevelopmental processes, 
early use of APDs has the potential to cause long-term alterations to normal brain 
functioning. 
 
 Aims 2.3.2
As discussed above, the general aim of this study was to investigate whether juvenile 
APD treatment, at a time where critical neurodevelopmental phases are occurring, 
would cause long-lasting, potentially permanent changes to behavioural attributes and 
the DA and 5-HT NT systems.  
 
The specific aims of this research study were: 
1. Investigate the effects of early APD treatment with aripiprazole, olanzapine and 
risperidone on long-lasting behavioural attributes, including social interaction, 
locomotor activity, anxiety-like and depressive-like behaviours. 
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2. Examine whether early treatment with the APDs aripiprazole, olanzapine and 
risperidone results in long-lasting alterations to  DA NT receptors, synthesis and 
re-uptake markers in key brain areas including the prefrontal cortex (PFC), 
caudate putamen (CPu), nucleus accumbens (NAc), hippocampus, substantia 
nigra (SN) and ventral tegmental area (VTA). 
 
3. Reveal whether early treatment with the APDs aripiprazole, olanzapine and 
risperidone causes long-term alterations to the key 5-HT receptors 5-HT1A, 5-
HT2A and 5-HT2C, involved in both the efficacy of APD action and the 
pathogenesis of mental illness, in key brain areas including the PFC, CPu, NAc 
and hippocampus. 
 
 Hypotheses 2.3.3
The hypotheses of this research studies were: 
1. Early treatment with the APDs aripiprazole, olanzapine and risperidone will 
result in long-lasting changes to locomotor activity, anxiety-like, depressive-like 
and social behaviours in across both male and female sexes, as these behavioural 
attributes have previously been associated to actions on DA and 5-HT receptor 
subtypes and subsequent modulation of the NT signal. (Chapter 3). 
 
2. Treatment with the APDs aripiprazole, olanzapine and risperidone during the 
critical neurodevelopmental time period will cause long-term changes to the 
density of DA D2 receptors in both the male and female cohort, with little effect 
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on the D1 receptor subtype. Subsequent alterations to TH and p-TH synthesis 
markers and DAT will also be uncovered. (Chapter 4). 
 
3. Juvenile treatment with aripiprazole, olanzapine and risperidone will result in 
long-lasting, permanent changes to the density of 5-HT2A receptor subtypes 
through multiple brain regions across both the male and female cohorts. 
Alterations to the 5-HT1A and 5-HT2C receptor subtypes will also be present, 
however to a lesser extent. (Chapter 5). 
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CHAPTER 3 - EARLY ANTIPSYCHOTIC TREATMENT 
IN CHILDHOOD/ADOLESCENT PERIOD HAS LONG-
TERM EFFECTS ON DEPRESSIVE-LIKE, ANXIETY-
LIKE AND LOCOMOTOR BEHAVIOURS IN ADULT 
RATS 
 
Journal article was published in De Santis, M, Lian, J., Huang, X-F., and Deng, C. Early 
antipsychotic treatment in childhood/adolescent period has long-term effect on 
depressive-like, anxiety-like and locomotor behaviours in adult rats, Journal of 
Psychopharmacology, 30(2), 204-214. Copyright © 2016 SAGE Publications. 
Reprinted by permission of SAGE Publications. DOI: 
https://doi.org/10.1177/0269881115616383.  
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CHAPTER 4 - EARLY ANTIPSYCHOTIC TREATMENT 
IN CHILDHOOD/ADOLESCENT PERIOD HAS LONG-
TERM EFFECTS ON THE DOPAMINE 
NEUROTRANSMITTER SYSTEM IN ADULT RATS 
 
Published in International Journal of Molecular Sciences 17(11): 1944, De Santis, M, 
Lian, J., Huang, X-F., and Deng, C. Early Antipsychotic Treatment in Juvenile Rats 
Elicits Long-Term Alterations to the Dopamine Neurotransmitter System, © 2016 by 
the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution (CC-
BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
 
 
 
 
 
 
 
Michael De Santis  63 
 
 
Michael De Santis  64 
 
 
Michael De Santis  65 
 
 
Michael De Santis  66 
 
 
Michael De Santis  67 
 
 
Michael De Santis  68 
 
 
Michael De Santis  69 
 
 
Michael De Santis  70 
 
 
Michael De Santis  71 
 
 
Michael De Santis  72 
 
 
Michael De Santis  73 
 
 
Michael De Santis  74 
 
 
Michael De Santis  75 
 
 
Michael De Santis  76 
 
 
Michael De Santis  77 
 
 
Michael De Santis  78 
 
 
Michael De Santis  79 
 
 
Michael De Santis  80 
 
 
Michael De Santis  81 
 
 
Michael De Santis  82 
 
 
Michael De Santis  83 
 
CHAPTER 5 - EARLY ANTIPSYCHOTIC TREATMENT 
IN JUVENILE RATS ELICITS LONG-TERM 
ALTERATIONS TO THE ADULT SEROTONIN 
RECEPTORS 
 
Published in Neuropsychiatric Disease and Treatment 14:1569–1583, De Santis, M., 
Huang, X-F., and Deng, C. Early Antipsychotic Treatment in Juvenile Rats Elicits 
Long-term Alterations to the Adult Serotonin Receptors. Supplementary figures are 
included in Appendix C2. © 2018 De Santis et al. This work is published by Dove 
Medical Press Limited, and licensed under a Creative Commons Attribution License. 
The full terms of the License are available at 
http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source 
are credited. 
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CHAPTER 6 - GENERAL DISCUSSION 
6.1 Overall Discussion 
As previously outlined, significant increases in the prescription and use of APDs in the 
juvenile population has occurred in recent years, despite a serious lack of understanding 
of the long-term effects of treatment. APDs such as aripiprazole, olanzapine and 
risperidone are known to produce their therapeutic effects through a potent affinity for 
and mechanism of action on DA and 5-HT receptors. The DA and 5-HT NT systems are 
also known to undergo and have a significant role in brain development during the 
critical neurodevelopmental period of childhood and adolescence (Levitt et al. 1997; 
Frost and Cadet 2000; Andersen 2003; Klomp et al. 2012; Milstein et al. 2013; Cousins 
and Goodyer 2015), and previous investigations have correlated alterations to the DA 
and 5-HT NT systems with changes in various behavioural attributes, and the 
pathogenesis of various mental illnesses (Meltzer and Huang 2008; Seo et al. 2008; 
Kegeles et al. 2010; Beaulieu and Gainetdinov 2011; Howes et al. 2012; Meltzer 2012; 
Ellenbroek and Cesura 2015; Teissier et al. 2015). There is therefore the potential that 
use of APDs during this phase of neurodevelopment may result in permanent or long-
lasting alterations to NT systems including that of DA and 5-HT as well as behaviours.  
 
The studies presented in Chapters 3 to 5 of this thesis therefore investigated the effects 
of early use of the commonly prescribed APDs aripiprazole, olanzapine and risperidone 
on potential long-term alterations to behavioural attributes, and changes to the DA and 
5-HT NT systems in adulthood. With in-depth discussions for each study included 
within Chapters 3 to 5 of this thesis, this chapter will provide a general discussion 
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around the key outcomes that have been achieved, and potential mechanisms for 
observed alterations based on interactions between the examined behaviours and the DA 
and 5-HT NT systems. Finally, limitations and recommendations of avenues for further 
research will be addressed. 
 
6.1.1 Provided Evidence that Juvenile Antipsychotic Drug 
Treatment Elicits Long-term Changes to Adult Behavioural 
Attributes and the DA and 5-HT NT Systems   
In Chapter 3 of this thesis (De Santis et al. 2016), the long-term effects of juvenile APD 
treatment on adult behavioural attributes in rodents was investigated. Evidence has 
subsequently demonstrated that early APD treatment with aripiprazole, olanzapine and 
risperidone results in long-term alterations to locomotor activity, anxiety and 
depressive-like behaviours in both the male and female animal models. Based on the 
premise of the uncovered behavioural changes and knowledge of the established basis 
of physiology from the literature, investigations into both the DA (Chapter 4) and 5-HT 
(Chapter 5) NT systems were also conducted, and alterations across both NT systems 
was also found. 
 
As described in Chapter 3, this thesis has demonstrated that locomotor activity levels 
were altered in both the male and female cohort following early APD treatment with 
both olanzapine and risperidone.  Although contrasting effects were uncovered across 
sexes (discussed in Section 6.1.3 below), the physiology behind changes to locomotor 
activity behaviours can been directly linked to alterations to the production and 
Michael De Santis  101 
 
transmission of the NT and density of receptors in the DA and 5-HT NT systems (Seo et 
al. 2008; Choi et al. 2010; Beaulieu and Gainetdinov 2011; Teissier et al. 2015; Wong-
Lin et al. 2017), as discussed in Chapters 1 and 3. Given the findings in Chapter 3 that 
early treatment with risperidone and olanzapine (to a lesser extent) significantly 
increased numerous behavioural parameters indicative of locomotor activity in the male 
cohort, it is interesting to find that corresponding increases to p-TH and DAT levels 
were detected in the PFC, hippocampus and VTA respectively, along with reduced 
levels of 5-HT2A receptor density levels in similar brain regions. The findings discussed 
in Chapters 4 and 5 across both the male and female cohorts are in support of the results 
of current studies that theorise that early exposure to the potent DA receptor antagonist 
mechanisms of risperidone and olanzapine may have resulted in long-term changes to 
the DA NT system, including an enhancement/up-regulation of DA synthesis and re-
uptake markers in brain regions previously linked to hyper-locomotor activity in males, 
with converse correlative effects in females once again in cortical and hippocampal 
brain regions (Beaulieu and Gainetdinov 2011; Shu et al. 2014). Furthermore, although 
limited changes to the D1 or D2 receptors were observed in Chapter 4, they were in line 
with previous results in a similar long-term APD treatment model (Vinish et al. 2012; 
Milstein et al. 2013), and may be due to the ongoing maturational/developmental phases 
of DA receptors as discussed in Chapter 1. Specifically, the receptor density levels of 
monoamine NT systems including DA are known increase significantly before a period 
of regressive elimination into adulthood (Dinopoulos et al. 1997; Andersen 2003; 
Andersen and Navalta 2004). It is during this period of regressive elimination that APD 
treatment was ceased in the current animal treatment model and hence a return to 
‘normal’ receptor density levels may have occurred, whilst the production/synthesis rate 
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of the DA NT and re-uptake marker (DAT) may still be left elevated. This may 
potentially be due to the antagonist actions of APDs on DA receptors including the D2 
autoreceptor (known to play a critical role in the regulation of DA synthesis) during the 
early neurodevelopmental phase. Along with increases to synthesis and re-uptake 
markers in the DA NT system found in Chapter 4, the reductions to the density of the 5-
HT2A and 5-HT2C receptors in the PFC and hippocampus discussed in Chapter 5 are also 
in line with the observed increases to locomotor activity levels of Chapter 3. With 
previous studies linking a deficient neurotransmission of 5-HT to a disinhibited and thus 
elevated DA signal (Kusljic et al. 2003; Seo et al. 2008), and 5-HT2A and 5-HT2C 
receptor activation known to have opposing effects on the DA release (Alex and Pehek 
2007; Howell and Cunningham 2015), there is collectively a clear potential association 
between the observed locomotor behaviours and contrasting alterations to the 
physiology in both the DA and 5-HT NT systems. 
 
Further to the observed changes to locomotor activity behaviours, Chapter 3 also details 
the uncovered alterations to anxiety- and depressive-like behaviours found across 3 
APD treatment groups, with contrasting effects across sexes again observed. 
Correlations between the observed alterations to anxiety-like and depressive-like 
behavioural parameters in both sexes, and the previously described changes to the 5-HT 
and DA NT systems (discussed in Chapters 4 and 5) can again be drawn. Collectively, 
the observed decreases to 5-HT2A and 5-HT2C receptor subtypes in cortical and 
hippocampal brain regions described in Chapter 5, together with the uncovered 
increases to DA synthesis and re-uptake markers detailed in Chapter 4, are in line with 
the findings of previous studies which have correlated reductions to the density of 5-
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HT2A and 5-HT2C receptors and decreased serotonergic signalling (Mora et al. 1997; 
Andersen and Navalta 2004; Karl et al. 2006; Seo et al. 2008), and associated alterations 
to DA signalling (Dunlop and Nemeroff 2007; Seo et al. 2008; de Oliveira et al. 2009) 
with anxiolytic and decreased depressive-like behaviours, as observed in Chapter 3 of 
this thesis.  
 
 
6.1.2 Provided Evidence that Juvenile Antipsychotic Drug 
Treatment with Aripiprazole, Olanzapine and Risperidone 
Causes Differing Long-term Effects  
As discussed in Chapters 3-5, early treatment with aripiprazole, olanzapine and 
risperidone was found to result in differing effects on long-term behaviours and the DA 
and 5-HT NT systems in the adult brain. Whilst early treatment with olanzapine and 
risperidone was found to result in long-term widespread, sex-specific effects across the 
3 investigations, early aripiprazole treatment was found to have minimal effects on adult 
behavioural attributes (as discussed in Chapter 3), yet still result in sex-dependent 
changes to the DA (Chapter 4) and 5-HT (Chapter 5) NT systems. 
 
Specifically, the high occupancy, partial agonist effects of aripiprazole on the DA D2 
receptor was seen to result in long-term decreases to DA synthesis markers in 
mesocortical regions of both the male and female cohorts, whilst its antagonist actions 
on 5-HT2A receptors was seen to result in similar correlative decreases to the 5-HT2A 
receptor in the hippocampus. Increases to 5-HT2C receptor density levels in the 
hippocampus of males were also uncovered following early aripiprazole treatment, 
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together with decreases in the PFC. The observed contrasting changes may be due to 
both the varied regional capabilities of the 5-HT2C receptor to tonically 
regulate/modulate DA signalling from the terminal regions (e.g. hippocampus) of 
mesolimbic and nigrostriatal pathways, something that is yet to have been proven in the 
mesocortical pathway as discussed in Chapter 1 (Section 2.2.3.3) (Kapur and 
Remington 1996; Abi-Dargham et al. 1997; Kusljic et al. 2003; Alex and Pehek 2007). 
Together with the observed changes to DA synthesis markers TH and p-TH uncovered 
in the PFC in Chapter 4, these regional variations in the relationship between the 5-
HT2C receptor and DA signal provides a foundational basis for the regional differences 
in aripiprazole treatment effects.  
 
In contrast, early treatment with the high affinity, antagonist actions of olanzapine and 
risperidone on 5-HT2A, 5-HT2C and DA D2 receptors was found to have more 
widespread, sex specific effects across all 3 investigations. As discussed in Chapter 3 
and Section 6.1.1 above, sex based and somewhat contrasting changes to locomotor 
activity, anxiety- and depressive-like behaviours were found across both the olanzapine 
and risperidone drug treatment groups, whilst the effects of early treatment with 
olanzapine and risperidone on the DA and 5-TH NT systems respectively, and potential 
reasons for the differences in effects are detailed and discussed in Chapters 4 and 5. 
Specifically, the antagonist actions of olanzapine on both the pre- and post-synaptic DA 
D2 receptor (inclusive of the D2 autoreceptor, with its regulatory functions) was found 
to affect the DA NT system of the female cohort only, decreasing the DA synthesis 
marker p-TH by 60% in the PFC, and increasing the adult density levels of the D2 
receptor in both the PFC and NAc of the mesocorticolimbic DA pathway. Furthermore, 
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olanzapine’s high affinity, inverse agonist actions on 5-HT2A and 5-HT2C receptors was 
found to decrease 5-HT2A receptor density levels of females and the 5-HT2C receptor of 
males only. In risperidone treated animals, increases to p-TH levels were observed in 
the PFC and hippocampus and decreases to D1 receptors were observed in contrast to 
the effects of olanzapine, whilst increases to 5-HT2C receptors were observed.  
 
The higher affinity, more potent antagonist actions of risperidone on the DA NT system 
receptors in comparison to olanzapine may be resulting in the different long-term effects 
of the APDs on the DA NT system. Furthermore, with a similar inverse agonist 
mechanism of action of olanzapine and risperidone on the 5-HT2A and 5-HT2C receptor 
subtypes (Meltzer and Massey 2011), it is interesting that whilst early treatment with 
olanzapine decreased 5-HT2A and 5-HT2C receptor levels in the female and male cohorts 
respectively, and risperidone was similarly found to decrease male 5-HT2A density 
levels in the PFC and hippocampus, increases to 5-HT2C receptors were found in the 
hippocampus of risperidone treated animals. Whilst both the higher affinity of 
olanzapine for the 5-HT2C receptor (Meltzer 2002; Meltzer and Massey 2011) and the 
aforementioned different regional capabilities of the 5-HT2C receptor to regulate the DA 
signal may play a role in this contrasting change (Kapur and Remington 1996; Abi-
Dargham et al. 1997; Kusljic et al. 2003; Alex and Pehek 2007), the higher level of 
constitutive activity of 5-HT2C receptors in comparison to its counterpart may also 
provide some basis of understanding for the observed differences in long-term effects 
(Berg et al. 2005), although further investigations into this may provide further clarity. 
The findings of this thesis has provided further evidence for, and highlighted the 
potentially fundamental role and intricate regional differences of the relationship that 
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the 5-HT NT system plays in the regulation of the DA signal, in particular the 5-HT2C 
receptor.  
 
 
6.1.3 Revealed that Juvenile Antipsychotic Drug Treatment 
Elicited Different Long-term Changes Across Sexes to Adult 
Behavioural Attributes, and the Dopamine and Serotonin 
Neurotransmitter Systems 
As discussed in Chapters 3-5 and briefly in Sections 6.1.1 and 6.1.2 above, early APD 
treatment with aripiprazole, olanzapine and risperidone was surprisingly found to result 
in sex-specific effects across all 3of the investigations detailed in this thesis. 
 
In Chapter 3, contrasting alterations were uncovered across locomotor activity, anxiety- 
and depressive-like behavioural attributes upon comparison of the male and female 
cohorts. Specifically, whilst early APD treatment in the male cohort resulted in 
behavioural attributes indicative of increased locomotor activity levels and decreased 
anxiety-like and depressive-like behaviours, on the contrary, treatment in the female 
cohort was found to result in changes to behaviours indicative of decreased locomotor 
activity and increased depressive-like behaviour, with no change in anxiety-like 
behaviour in comparison to the control group. As detailed in Chapter 4 above, the 
contrasting and sex-specific effects observed in Chapter 3 were again uncovered in the 
DA NT system upon comparison of male and female cohorts.  Specifically, whilst early 
treatment with aripiprazole and olanzapine was found to result in decreases to DA 
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synthesis markers, and increases to D2 receptor density levels were uncovered following 
olanzapine treatment in the female cohort, both increases to DA synthesis and re-uptake 
markers were found in the male cohort following risperidone drug treatment, and 
furthermore minimal effects were observed in the olanzapine and aripiprazole drug 
treatment groups. Finally, sex-specific alterations were similarly observed in 
investigations into the 5-HT NT system. As detailed in Chapter 5, whilst alterations to 
5-HT2A and 5-HT2C receptors were uncovered in cortical and hippocampal brain regions 
of male animals across all 3 drug treatment groups, a lone decrease to the 5-HT2A 
receptor was uncovered in the hippocampus of olanzapine treated female rats. 
 
Overall, there are numerous potential factors that need to be deliberated when 
considering the reasons for sex-specific variances observed in the results across all 3 
studies (Chapters 3-5). Firstly, as detailed in Chapter 1, it is well known that there are 
significant differences in the timeline of neurodevelopmental phases between the male 
and female brain, including that of the monoamine NT systems DA and 5-HT 
investigated in this thesis (Andersen and Teicher 2000; De Bellis et al. 2001; Andersen 
2003). Specifically, sex differences have been found of the age and rate that 
myelination, synapse and receptor production and elimination occurs within both the 
DA and 5-HT NT systems (Andersen and Teicher 2000; Andersen 2003), as well as the 
individual neurodevelopmental differences between specific receptor subtypes and brain 
regions (Andersen 2003; Sinclair et al. 2014). Furthermore, previous results have also 
highlighted that basic differences between males and females on a biological level 
(Bolea-Alamanac et al. 2018) also provides a potential reasoning for the observed sex 
differences in affects. Additionally, the well documented influence of the sex hormones 
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estrogen and testosterone on the development of the DA and 5-HT NT systems, 
including the synthesis of each ligand and density of numerous receptor subtypes within 
each NT system also highlights their capability to impact the observed results (Sumner 
and Fink 1993; Sumner and Fink 1995; Zhang et al. 1999; Andersen 2003; Gogos et al. 
2010; Gogos et al. 2012; Purves-Tyson et al. 2012; Purves-Tyson et al. 2014; Sinclair et 
al. 2014; Bolea-Alamanac et al. 2018). Furthermore, a potential ‘neuro-protective’ role 
of estrogen on the DA and 5-HT NT systems has also been uncovered in some 
investigations (Dunlop and Nemeroff 2007; Gogos et al. 2012), and once carries the 
potential to influence results. Further studies into the role of the sex hormones 
testosterone and estrogen on shaping the DA and 5-HT NT systems, and its thus a 
potential neuroprotective role through the period of neurodevelopment will shed further 
light on its exact capabilities to influence the potential long-term effects of early APD 
treatment that were observed in the current thesis. 
 
 
6.2 Recommendations for Further Research 
In reflecting on the findings of this thesis, the following are recommendations of areas 
in which further research will provide greater insight into the potential long-term effects 
of juvenile APD treatment on the adult brain: 
a) The DA NT system is well known to play a critical role in both the pathogenesis of 
mental illness, and as a pharmacological target of APD treatment. This thesis 
uncovered that juvenile treatment with the APDs including aripiprazole, olanzapine 
and risperidone caused alterations to DA synthesis markers, transporter and D1 and 
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D2 receptor density levels across mesocortical, mesolimbic and nigrostriatal 
pathways (Chapter 4). Further investigations however into potential long-term 
effects on the DA D3 receptor, also known to play a role in the therapeutic benefits 
of APD actions, would provide further insight into the scope of long-term effects on 
the adult brain.  
 
b) The investigations in Chapter 5 revealed that 5-HT2A and 5-HT2C receptor density 
levels were altered in cortical and hippocampal brain regions long-term, following 
early treatment with the APDs aripiprazole, olanzapine and risperidone. With the 
scope of the completed study into the 5-HT system only spanning the PFC, NAc, 
CPu and hippocampus (as tissue had already been collected), further investigations 
conducted into brain regions including the RN will reveal to a greater extent 
potential long-term changes to the 5-HT system. Known to play a key role in the 
synthesis/production of the 5-HT NT (Choi et al. 2012), investigations into the 
effects of early treatment on 5-HT synthesis markers will also provide into the 
effects of early APD treatment on the production and transmission of a NT known 
to play numerous critical functions within the brain. Furthermore, additional studies 
into potential changes to other 5-HT receptor subtypes in the hippocampus including 
5-HT4, 5-HT6 and 5-HT7 will provide greater insight into the full array of potential 
effects of early APD treatment, with the region and receptors known to play a 
critical role in cognitive and memory capabilities (Berumen et al. 2012). 
 
c) The current thesis aimed to establish whether APD treatment had the capability to 
result in any long-term behavioural changes, and subsequently behavioural tests 
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investigating numerous behavioural attributes were selected. The results of the 
investigations have subsequently thrown to light the need for further investigations 
into both the potential effects of early APD use on other behaviours (e.g. object 
recognition, pre-pulse inhibition etc.), and also the benefits that extensive testing 
into the uncovered behavioural changes would have, including the light-dark 
transition test to further investigate anxiety-like behaviours, which we now 
recommend be carried out. 
 
d) Investigations into the potential for long-term physiological alterations on other NT 
systems known to play a critical role in the physiology of the behavioural attributes 
investigated will also provide insight into potential further, more extensive effects 
across numerous NT systems. The noradrenergic, glutamate and GABA NT systems 
are all well-known to play critical roles in the regulation of behavioural attributes 
observed in the current thesis, and furthermore are well-known to interact 
significantly with the DA & 5-HT NT systems in order to shape the NT signal. 
 
e) Whilst the current juvenile animal treatment model was utilised to investigate the 
effects of APD treatment in healthy rats, further studies across the numerous 
developmental animal models of mental illness (e.g. hippocampal lesion model for 
schizophrenia) will provide further knowledge on the potential long-term effects 
during the critical neurodevelopmental period. Thus far, investigations into the 
effects of adolescent treatment with APDs in animal models of mental illness have 
uncovered that early intervention can alter structural brain abnormalities long-term 
in a manner that precedes normal brain functioning (Piontkewitz et al. 2009; 
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Piontkewitz et al. 2012). With no single disease or genetic model capable of 
covering the wide-range of antipsychotic treatment conditions in 
children/adolescents, investigations across numerous animal models of mental 
illness will need to be completed to correctly investigate the effects of treatment 
across the numerous mental illnesses that APDs are currently used to treat, which 
fell outside the scope of the current thesis. 
 
f) With sex comparative differences in effects observed across all 3 studies (Chapter 3-
5), further investigations into the potential impact of the presence and absence of the 
sex hormones testosterone and estrogen will shed further light on the role of each in 
the observed changes. With estrogen and testosterone both known to play influential 
roles in the development and function of both the DA and 5-HT NT systems,  
investigations into the effects of both sex hormones on the long-term effects of 
juvenile APD in the DA and 5-HT systems will provide further insight into the 
potential role of each in the observed alterations. 
 
g) Although aripiprazole, olanzapine and risperidone were selected and utilised in the 
current investigations as they are three of the most commonly prescribed/used APDs 
in the juvenile population (Haw and Stubbs 2007; Vitiello et al. 2009; Olfson et al. 
2010; Sharma and Shaw 2012; Memarzia et al. 2014; Schneider et al. 2014), 
consideration also needs to be given to the various other APDs currently being 
prescribed to children and adolescents. Therefore, further investigations into the 
potential long-term effects of other APDs widely used in the treatment of psychosis 
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related disorders (e.g. clozapine) will also provide a greater insight into the effects 
of early APD use on the adult brain. 
 
h) Whilst the current studies have demonstrated that early APD treatment with 
aripiprazole, olanzapine and risperidone caused long-term changes to both the DA 
and 5-HT NT systems in an in vivo animal model, the potential effects in a clinical 
setting is currently not well understood. With APD use in the child and adolescent 
population still currently increasing globally, extending the premise of the current 
investigation into the clinical setting and across multiple brain regions will provide 
further, more clinically relevant information to clinicians on the long-term 
implications of early APD prescription and use. 
 
 
6.3 Conclusions and Implications 
In conclusion, the series of investigations that is encompassed in this thesis has 
demonstrated that APD treatment in juvenile rodents has the capability to cause sex and 
drug specific long-term alterations to various behavioural attributes in adulthood. With 
the knowledge that both the DA and 5-HT NT systems play a vital role in the 
physiology behind investigated behavioural attributes, this thesis has also provided 
evidence that early treatment with the high affinity, potent agonist/antagonist actions of 
aripiprazole, olanzapine and risperidone on the DA and 5-HT NT systems has the 
capability to cause sex, drug and region specific long-term alterations to DA receptors, 
synthesis and re-uptake markers, and furthermore 5-HT receptors in the adult brain. 
These results hence confirm that treatment with the APDs aripiprazole, olanzapine and 
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risperidone during a time that critical neurodevelopmental phases are occurring has the 
potential to cause long-lasting and potentially permanent alterations to both the DA and 
5-HT NT systems, and furthermore implicate a potential correlation with the observed 
changes to various physiologically related behavioural attributes. Whilst detected 
alterations to locomotor activity, anxiety- and depressive-like behaviours were 
uncovered following the investigations within the scope of the current thesis, further 
behavioural and cognitive tests may reveal a more extensive array of long-term changes 
caused by this early insult of APDs, with both the DA and 5-HT NT systems known to 
play critical roles in numerous cognitive abilities from working memory to sensory and 
motor processes (Carlsson et al. 2004; Dolžan et al. 2008; Teissier et al. 2015). 
 
 
The findings from the present investigations provide an initial examination into the 
potential long-term effects of 3 APDs widely and increasingly prescribed in the juvenile 
population (Vitiello et al. 2009; Zuddas et al. 2011), in an area where there is a need for 
further information around the safety of its use long-term. Further and more extensive 
investigations over short and long-term time periods to uncover the full array of 
potentially permanent effects that the potent actions of APD prescription and use may 
have on the juvenile brain will provide further evidence of the alterations to both the 
neural topography and functioning in adulthood. A well-established evidence base will 
allow psychologists/psychiatrists to weigh up the risk/benefit ratio of prescribing APDs 
to the juvenile population, with alternative treatment options potentially addressed first 
(Haw and Stubbs 2007; Vitiello et al. 2009; Memarzia et al. 2014). Furthermore, 
clinical tools/assessments to monitor the risks and benefits associated with juvenile 
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APD prescription and use clinically will also provide an additional tool for valuation of 
the risk/benefit ratio of use. 
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Supplement C2 – Supplementary Figures from Chapter 5 Investigation 
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